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Abstract
Metachromatic leukodystrophy (MLD) is an inherited lysosomal storage disease caused by
deficient arylsulfatase A (ARSA) activity, resulting in intra-lysosomal accumulation of
sulfatide. Sulfatide is integral for proper maintenance of myelin in the central and peripheral
nervous systems. This study characterized mitochondrial morphology, cytokine secretion and
phagocytic activity in Schwann and mesenchymal cells isolated from ARSA-/- mice. Cells were
treated with different, increasing concentrations of sulfatide for a period of 24 hours. ARSA-/cells presented with persistent, increased fragmented mitochondrial structures suggestive of
prolonged mitochondrial fission. Sulfatide treatments increased secretion of pro-inflammatory
cytokines TNF-α and IL-1β in ARSA-/- cells. No differences were noted in the cellular
phagocytic capacities following sulfatide treatment. These findings suggest that mitochondrial
function is impacted. Further characterization of in vivo mitochondrial function in MLD tissues
can provide a clearer pathological picture.
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Summary for Lay Audience
Metachromatic leukodystrophy (MLD) is a rare, fatal nervous system disease that mainly
affects children. At 1 year of age, children develop difficulties with walking, speech, mental
abilities, and vision. MLD is caused by the loss of an enzyme, known as arylsulfatase A
(ARSA) that functions in the recycling centers of the cell (known as lysosomes). ARSA breaks
down sulfatide, an important lipid that has a role in the development and function of white
matter (an insulating tissue that allows nerve signals to travel throughout the body) in the brain
and peripheral nerves. In MLD, new sulfatide is constantly made despite the accumulation of
sulfatide due to the absence of ARSA. Numerous efforts at correcting this disease have had
varied success and only impacted brain-associated symptoms. Destruction of peripheral nerves
continued in patients suggesting that sulfatide accumulation has different consequences across
tissue and cell types.
Research in diseases like MLD has shown improper lysosomal accumulation causes other
cellular organelles to function inappropriately. The collective dysfunction in multiple cellular
components is thought to contribute to eventual cell death. Some components examined
include mitochondria (cellular energy producing centers) and immune responses to stress such
as cytokine secretion (ability of the cell to release signaling molecules to recruit outside help)
and phagocytosis (process used to engulf and degrade abnormal and/or foreign particles). We
harvested Schwann and mesenchymal stromal cells from mice that lack ARSA to characterize
the impact of sulfatide on cells outside the brain. Cells were treated with increasing amounts
of sulfatide, over 24 hours. Unlike healthy cells, MLD cells displayed mitochondria that were
small and fragmented. Persistence of fragmented mitochondria for 24 hours is suggestive of
irregularities in mitochondrial function. We also noticed that MLD cells release cytokines
TNF-α and IL-1β when exposed to sulfatide. We saw no change in the phagocytic ability in
sulfatide treated cells. Taken together, these results suggest that mitochondrial function in
MLD cells is impacted by sulfatide-induced stress. Going forward, deciphering details of
different mechanisms involved in this increased cellular sensitivity as it relates to slower, more
progressive accumulation of sulfatide can help us design more effective therapies.
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Chapter 1
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Introduction

Lysosomal storage diseases (LSDs) are a large group of more than 60 different inherited
diseases that are characterized by abnormal accumulation of various metabolites in the
lysosomes due to specific lysosomal enzyme deficiencies. Though individually rare,
collectively these diseases have an incidence of 1:5000 live births, comparable to the health
burden generated from disorders such as cystic fibrosis1,2. Metachromatic leukodystrophy
(MLD; OMIM#250100) is an autosomal recessive LSD that is characterized by a
deficiency in arylsulfatase A (ARSA) enzyme activity. This deficiency results in the
impaired catabolism of a class of acidic glycolipids known as sulfatides3. Intracellular
accumulation of sulfatide is mostly apparent in myelinating cells such as oligodendrocytes
in the central nervous system (CNS) and Schwann cells in the peripheral nervous system
(PNS); where accumulation of sulfatide causes progressive demyelination4. When
considering MLD, prevailing theories of pathogenesis have centered around the disruption
of lysosomal function as being the most relevant contributor to the disease. However,
attempts at addressing the lysosomal storage alone thorough enzyme replacement and/or
gene therapy have been variable at treating the disease, particularly as the disorder
progresses. In parallel, the growing body of evidence of a multi-organelle and chronic
inflammatory contribution to the progression of metabolic diseases such as LSDs raises the
question of whether we are oversimplifying a very complex and intricate disease
pathogenesis? The lack of clarity about cellular pathogenesis in MLD presents a strong
need for increased research efforts in understanding specific components of cellular
impact, to better target therapies at different stages of the disease progression. This study
investigates the acute impact of sulfatide in MLD cells as it pertains to mitochondrial
function and immune responses.
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1.1
1.1.1

Metachromatic Leukodystrophy
Clinical Features

Arylsulfatase A deficiency (also known as MLD), is a rare, autosomal recessive lysosomal
sphingolipid storage disorder. ARSA, a lysosomal hydrolase that degrades cerebroside-3sulfates (sulfatides), a group of sphingolipids that are predominantly found in myelin4.
Deficient ARSA enzyme activity impairs degradation of sulfatide, resulting in endolysosomal and extra-cellular accumulation (i.e. storage) of the substrate. As sulfatide
makes up to 4% of the neuronal myelin sheath, contributes to its structural stability and
regulates mechanisms of oligodendrocyte and Schwann cell differentiation, the primary
clinical manifestations are neurological and fatal in all forms of the disease5–7. The three
main subtypes of MLD are categorized based on age of disease onset: late infantile – 5060%, juvenile – 20-30%, and adult – 15-20%4. Clinical presentations vary across
individuals depending on the specific type of MLD. Affected individuals present with
widespread neurological and multi-organ symptoms such as deteriorating intellectual and
motor skills, and loss of sensation in extremities (Figure 1.1)4. Interestingly, the clinical
presentation of peripheral neuropathy is even more varied than the CNS symptoms.
Diagnosis can be established with clinical presentations, elevated urinary sulfatides
(usually not measured routinely), and magnetic resonance imaging (MRI). MRI evidence
of leukodystrophy, enzymological confirmation of ARSA deficiency and identification of
two pathogenic ARSA variants2,4.
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Figure 1.1 Summary of MLD clinical presentation.

1.1.2

Genetic and Biochemical Impact of MLD

LSDs are monogenic and inherited in an autosomal recessive manner, with some
exceptions (e.g. Fabry’s disease, Hunter disease). Certain populations have a higher
incidence for particular LSDs, often due to either founder effects and/or cultural practices
resulting in increased incidence of consanguinity9. MLD is pan-ethnic and gender-equal in
impact. However, a higher prevalence has been identified in the following populations:
Polish (1:25000); Habbanite Jews, Israel (1:75); Israeli Arabs (1:8000); Inuit and Yupik
peoples (1:2500); Navajo Nation-USA (1:6400). More than 250 pathogenic variants have
been identified in ARSA, and mutation types (Supplementary Figure 1) encompass
missense (most common), nonsense, deletions, insertions, duplications, inversions and
splice variants4.
Biallelic pathogenic variants in the ARSA gene impair production of a fully functional
ARSA enzyme, resulting in deficient enzyme activity (<10-15% of normal enzyme activity
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in peripheral blood leukocytes). Some variants exist that result in a pseudodeficiency
(ARSA-PD) that results in the lower enzyme activity (15-20% of normal enzyme activity
in peripheral blood leukocytes) that is still sufficient to satisfy the requirements of a healthy
individual4. ARSA-PD becomes important in the context of diagnosis and screening based
on enzyme activity determination alone. Lysosomal hydrolases are part of a highly
regulated pathway that systematically breakdown different substrates. ARSA is produced
in the rough endoplasmic reticulum (ER) and modified by a N-acetylglucosamine-1phosphotransferase in the Golgi apparatus that results in the attachment of mannose-6phosphate (M6P) residues onto the enzyme10,11. These residues enable transport of the
enzyme from the trans Golgi network to various regions of the cell, including the
lysosome11. When in the acidic lysosomal environment, ARSA hydrolyzes sulfatide. The
enzymatic impact of pathogenic variants is variable, with residual activity being inversely
proportional to disease severity. It is important to note that there are no obvious genotypephenotype correlations in MLD, given that family members with the same genotype can
have phenotypic variability.

1.1.3

MLD Research Scope and Knowledge Gap

Numerous research groups have worked on developing an effective therapy in the form of
enzyme replacement therapy (ERT), substrate reduction therapy, and gene therapy3,12–16.
Gene therapy strategies have included the use of hematopoietic stem cells, mesenchymal
stromal cells (MSC), and embryonic stem cell transplants as well as direct injection of
ARSA-overexpressing viral vectors into the cerebroventricular space4. All approaches
center around the idea of cross-correction, through uptake of excess secreted enzyme by
distal cells. Interestingly, the hematopoietic stem cell transplantation and gene therapy
trials that have been conducted were effective at decreasing the sulfatide accumulation and
retaining proper CNS functions in asymptomatic patients17,18. However, none of the trials
were able to address peripheral neuropathy in the PNS. Given the low incidence and
presence of pseudodeficiency, screening and treating the disease prior to clinical
ascertainment becomes challenging.
Another aspect of therapy research that has recently been gaining prominence is the
emergence of a seemingly evolving natural history for the treated metabolic diseases. For
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example, Krabbe’s disease, another LSD caused by accumulation of the substrate
psychosine, results in a similar, devastating neurological disease. Newborn screening for
Krabbe’s, and subsequent cord transplantation in children were initially seen as
successful19. However, children who received these transplants have clinically presented
with peripheral neuropathy despite having relatively unaffected CNS functions. Similar
findings have been identified in therapeutic endeavors for other metabolic diseases with
neurological involvement, including MLD20. This challenges the notion that the CNS and
PNS disease pathologies are identical at a cellular level and warrants further investigation
to develop more comprehensive treatment approaches.

1.2
ARSA Deficiency – Implications on Cellular
Homeostasis
1.2.1

Biological Roles of Sulfatide

Sulfatide, a ceramide-based galactosphingolipid, is highly enriched in myelin in both the
CNS and PNS. At a cellular level, its synthesis starts in the ER and is then sulfated in the
Golgi apparatus by 3′-phosphoadenosine-5′- phosphosulfate: cerebroside sulfotransferase
(CST). It is eventually degraded specifically by ARSA through hydrolysis of the sulfate
group in the lysosomes. Sulfatide functions as a negative inhibitor for oligodendrocyte
differentiation in the CNS whereas it initiates myelination in cultured Schwann cells 21–23.
It is important to note that there may be sulfatide-independent pathways that contribute to
myelination of the PNS, as CST-deficient mouse models do not present with abnormal
myelination. Apart from involvement in various aspects of myelination, sulfatide has been
shown to function in different capacities in the immune system, acting as a ligand and/or
receptor for different proteins (e.g. P- and L-selectins) and chemokines6,11. Interestingly,
sulfatide has been suggested to participate in an anti-inflammatory manner. Animals
studies of autoimmune diseases, such as type I diabetes, have demonstrated reduced
apoptosis in β-cells, by blocking the secretion of cytokines and pro-inflammatory factors
such as interleukin-1β (IL-1β) and tumor necrosis factor-alpha (TNF-α). As a result of its
multifunctional role, the improper metabolism of sulfatides has several implications in
other human diseases such as Alzheimer’s disease, insulin secretion, and immune
abnormalities23.
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1.2.2

Disrupted Autophagy in MLD

Autophagy is a critical process of regulating cellular abnormalities and improving the
physiological environment in any part of the body. Under normal conditions, autophagy is
used to remove pathogens and damaged cells and modulate the body’s inflammatory
response. Depending on the route of transport of material to the lysosome, autophagy can
occur through 3 mechanisms: macroautophagy, microautophagy, and chaperon-mediated
autophagy. Substrates such as sulfatide are degraded through macroautophagic routes, with
the formation of a autophagosome that subsequently fuses with the lysosomal vesicles to
degrade the material24. Given the importance of the proper degradation of material to
maintain cellular homeostasis, it is not a surprise that autophagy contributes to both the
innate and adaptive immune systems as well as apoptosis. Lipids have been shown to play
an important role in regulating autophagy, such as ceramides promoting cell death, and
sphingosine 1-phosphate promoting survival. In LSDs, the macromolecule storage in
lysosomal compartments impairs the fusion of the autophagosome and lysosomes resulting
in the accumulation of autophagosomes25. In a neurological context, disruption of
autophagic processes, and subsequent accumulation of aggregated proteins and/or
substrates directly causes neurodegeneration. This type of neurodegeneration has also been
heavily documented in various aging-related neurological diseases such as Huntington’s,
familial Parkinson’s and Alzheimer’s26–28. In MLD, the intralysosomal storage of sulfatide
in Schwann cells, phagocytes, astrocytes, oligodendrocytes, neurons, and numerous other
cell types leads to demyelination in the CNS and PNS regions. The exact mechanisms
involved in the degeneration remain poorly understood.

1.3

The Peripheral Nervous System

The PNS enables communication through nerves and ganglia that extend from the brain
and spinal cord to the rest of the body. Though the CNS and PNS share many similarities,
a noted difference is the protective stringency of the blood-nerve barrier (BNB) in PNS
compared to the blood-brain barrier (BBB). Peripheral neuropathy in MLD is evident in all
form of the disease but is often masked by the progressive development of spastic
tetraparesis (a CNS manifestation)29. Unlike in the CNS, storage of sulfatide is not
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correlated with rate of demyelination and the presence of peripheral symptoms in MLD
individuals30,31. The following section introduces some fundamental aspects of the PNS.

1.3.1

The PNS Supporter Cell – The Schwann Cell

Schwann cells are the main glial cell population in the PNS and act in a variety of roles in
myelin biogenesis, myelin sheath formation and organization, and facilitation of myelin
repair32. Many research groups have contributed to the evidence that Schwann cells are
essential for axonal survival and PNS function and are the primary contributors to different
pathologies in neurodegenerative diseases32–34. Schwann cells de-differentiate into a
transient, immature state to promote axonal regeneration by inducing phagocytosis of
myelin debris, forming supportive tubular structures, and regulating and recruiting various
neurotrophic factors. This complex series of processes are highly regulated and result in
the Schwann cells re-differentiating back to their mature state and completing the
formation of the new myelin sheath, effectively restoring nerve function35. Interestingly,
axons in some MLD patients remain intact30, despite evidence of sulfatide storage and
increased apoptosis in Schwann cells.

1.3.2

Inflammatory Responses in the PNS

The CNS is generally thought to be immunoprotected as a result of the BBB. The series of
reactions following neuronal injury include activation of resident microglia, increases in
concentration of cytokines and BBB permeability. The dual impact of functional
lysosomal deficiency, and increased lipid accumulation disrupts the lysosomal membrane
integrity and cellular homeostasis. This increased permeability causes spillage of
lysosomal content into the cytosolic regions of the cell36, exposing an array of hydrolases,
cathepsins and debris, triggering the formation of inflammasome complexes37. Intrinsic
cellular homeostatic functions can also increase production of trophic factors, to activate
mechanisms that clear away debris and amplify the overall glial activation and
inflammatory response. This translates to a common phenomenon of chronic
neuroinflammation observed across numerous LSDs with CNS and PNS manifestations38.
This type of inflammatory response contrasts with the more transient response seen in acute
neuronal injury and the cellular mechanisms triggering and activating the
neuroinflammatory pathways remain elusive. The presence of neuroinflammation has been
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shown to precede neuronal loss, supporting the idea of inflammation contributing to
progressive neurodegeneration39.
In general, TNF-α and IL-1β are common proinflammatory cytokines that induce
autophagy40. IL-1β is part of a large family of interleukins and plays a pivotal role in the
immune system, acting as a precursor to the formation of the Caspase-1/Interleukin-1
converting enzyme (Caspase-1/ICE) inflammasome complex40. It is secreted in response
to infectious, bacterial, and inflammatory agents. Dysregulation of this cytokine is
implicated in numerous auto-immune diseases such as rheumatoid arthritis41, insulindependent diabetes mellitus41,42, and other pathological conditions such as neuronal
injuries and age-related neuronal disorders43. TNF-α is another critical cytokine that is
heavily involved in a wide range of physiological and pathological processes. It is a part
of a large family (TNF beta [TNF-β], CD40 ligand [CD40L], Fas ligand [FasL], and TNFrelated apoptosis inducing ligand [TRAIL]) that play varying roles in apoptosis and
systemic inflammation38,40. TNF triggers the nuclear factor kappa-light-chain-enhancer of
activated B cells (NF-ϰB) and mitogen-activated protein kinase (MAPK) signaling
pathways and is a key mediator in acute and chronic inflammatory responses, which is
capable of stimulating secretion of other proinflammatory cytokines.
There are reported examples of LSDs that have been shown to have links with chronic
inflammation. In Gaucher’s disease, the accumulating macromolecular, glucosylceramide
activates macrophages and causes the release of cytokines such as TNF-α, IL-1β and
chitotriosidase44. The release of these factors, induces recruitment of other immune cells
such as neutrophils, intensifying the immunological burden. Fabry’s disease
(globotriacylceramide accumulation) and mucopolysaccharidoses (MPS) diseases have
also demonstrated elevated secretion of proinflammatory cytokines IL-1β, interlukin-6 (IL6), and TNF-α, and increased oxidative stress, all contributing to these diseases45. In MLD,
increases in monocyte chemoattractant protein-1 (MCP-1),

interleukin-1 receptor

antagonist (IL-1Ra), interlukin-8 (IL-8), macrophage inflammatory protein-1beta (MIP1b) and vascular endothelial growth factor (VEGF) have been documented46. Many of
these cytokines act on the BBB and BNB, disrupting the integrity of the barrier. Though a
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hypothetical neuroinflammation model has been proposed in MLD, little patient-based
evidence is currently available to support these findings.

1.4
Mitochondria in Metabolism and Metabolic
Disease
1.4.1

The Complex World of Mitochondria

Mitochondria are dynamic organelles that participate in a wide range of cellular processes
including adenosine triphosphate (ATP) generation, metabolite synthesis, production of
reactive oxygen species (ROS), maintenance of cellular ionic homeostasis and apoptosis47.
They are active members in these numerous pathways by undergoing transport, fusion, and
fission. Mitochondria are made up of two bilipid membranes that compartmentalize the
organelle, separating the cytosol from the inner mitochondrial membrane. The inner
membrane is mostly composed of proteins and a small percentage of (20%) lipids, while
the majority of the outer membrane is composed of lipids48. This compartmentalization
allows for ionic gradients, generated through the passage of ions and molecules from the
intermembrane space to the inner matrix49. Respiratory levels impact the compactness of
the mitochondria, with high activity resulting in small, condensed structures. These have
enlarged cristae that are generated through compaction of the inner membrane away from
the outer membrane. Contrastingly, under low activity, the inner matrix volume is
increased, and the outer membrane pulls away from the inner membrane.
Mitochondria participate in apoptosis through their release of cytochrome c, which
regulates the assembly of caspase complexes that induce cellular degradation50. Protons
are pumped across the inner membrane as the electrons are transported through the electron
transport chain, creating a transmembrane difference of proton electrochemical potential
that is termed the mitochondrial membrane potential (MMP)51. ATP synthesis is then
fueled by the proton pools. Of note, it’s the mitochondrial membrane that stimulates
cytochrome c release52, suggesting that changes in membrane potential can be indicators
of mitochondrial and cellular health.
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1.4.2

Mitochondrial Fusion and Fission

The adaptive morphological changes of mitochondria occur in response to different cellular
stimuli (e.g. alteration of energetic demands, increased ROS)53. These morphological
changes occur through fusion and fission (Figure 1.2), two highly conserved, constitutive,
and opposing mechanisms that mitochondria undergo within the cell. Mitochondrial fusion
results in the creation of larger, more networked mitochondria while fission causes
mitochondrial division, fragmentation, and an increased number of mitochondria. Fusion
is thought to be a two-step process (in mammals) and is mediated by specific proteins, such
as the mitochondrial dynamin like GTPase (Opa1) and transmembrane dynamin-related
GTPases, mitofusins (Mfn1 and Mfn2) to promote fusion between the outer and inner
membranes of mitochondria54. The transmembrane regions in mitofusins Mfn1 and Mfn2
essentially form a “U-shaped” structure, tethering mitochondrial structures that will then
experience GTP hydrolysis-induced conformational changes leading to fusion54,55.
Interestingly, both mitofusins are differentially expressed55. Mfn2 expression is tissue
specific and upregulated during cellular stress55. The other step in the fusion process
involves Opa1 which largely localizes to the cristae in mitochondria (approximately 8% on
the inner mitochondrial membrane). Interactions between Opa1 and the “U-shaped”
topology caused by the mitofusins facilitates fusion54,55. Larger mitochondria are
associated with increased membrane potential and by extension, increased ATP
production55. In contrast, the fission process results in smaller units of mitochondria that
are more mobile and often fuse with the outer cellular membrane to go to regions with
increased energy demands. Fission allows cells to segregate healthy and dysfunctional
mitochondria, targeting the latter to mitophagy47,56. Cells in mammalians are thought to
utilize fission-associated proteins, dynamin related protein-1 (Drp1) and fission protein
(Fis1) to undergo a one-step process to fragment mitochondria54,56. Drp1 localizes
primarily to the cytosol (approximately % on mitochondria) and plays important roles in
calcium signaling, mitochondrial fission and apoptosis47,56. During fission, Drp1
oligomerizes into an “X-shaped” dimer on the outer mitochondrial membrane, with the
help of other mitochondrial specific-proteins, creating a constricted region that is
subsequently excised47,56. This splitting involves a different set of proteins such as actin
and myosin filaments. Fis1 is distributed evenly throughout the outer mitochondrial
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membrane and is thought to function as a receptor for fission-associated proteins56. Of
importance, Drp1-independent fragmentation mechanisms54 exist and also contribute to the
regulation of mitochondrial fission. A balance between fusion and fission is important for
the proper function of mitochondria in axons57. Disturbances or imbalance to either process
can be detrimental to axonal growth and maintenance, both of which are energy intensive.

Figure 1.2 Fusion and fission process cause morphological changes.

1.4.3

Importance of Mitochondria in Schwann Cells

The PNS connects the CNS with the organs and extremities in the periphery. To enable
proper signal transmission from the CNS, the neurons in the PNS interact heavily with
Schwann cells that function in supporting nerve function and axonal maintenance through
myelin insulation. Metabolically active and energetically demanding cells such as neurons
and Schwann cells require a very precise maintenance of mitochondrial function58.
Mitochondria cater to the differential bioenergetic requirements of tissues across the body
by altering their abundance, motility, and morphology through the facilitation of fusion
and fission processes. Mitochondrial functional studies demonstrated that in non-injured
peripheral nerves, the mitochondrial pool, mostly remains stationary. However, following
injury, mitochondria in peripheral nerves demonstrate a drastic increase in motility,
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towards the injury site57. One study in Caenorhabditis elegans (C. elegans)59 examined the
density of the mitochondria in non-regenerating and injured axons. Density increases in
regions that have been injured and are under process of regeneration as a result of increased
fission, with reduction of density negative impacting axonal regrowth. This is of
importance because it highlights the active role mitochondria play in pathological
conditions.

1.4.4

Mitochondrial Dysfunction in Neurodegenerative and
Metabolic Diseases

Given the close relationship established between cellular metabolism and mitochondrial
function, it is conceivable that mitochondrial dysfunction may play a central role in
neurodegenerative diseases. In that vein, LSD researchers have proposed a pathological
cascade (Figure 1.3) that postulates other cellular contributors, in addition to the lysosomal
dysfunction. Briefly, the accumulation of macromolecular substrates is thought to result in
reduced autophagic flux, leading to several negative downstream implications, including
in the mitochondria58. This mitochondrial dysfunction causes dysregulation of Ca2+
homeostasis, increased reactive oxygen species production and aberrant inflammatory and
apoptotic signaling with the collective negative impact affecting overall cellular function
and health58. Studies have described mitochondrial dysfunction and derangements in
numerous forms of peripheral neuropathy as seen with morphological abnormalities and/or
respiratory chain enzyme activities changes in sural nerves in animal models for diabetes
60,61

, antiretroviral treatment62 or in a number of Charcot-Marie-Tooth (CMT) disease

subtypes63. Abnormal mitochondrial morphology, decreased membrane potential,
increased generation of ROS and reduced ATP production have been reported in other
LSDs, such as Gaucher disease, MPS, mucolipidosis types I-III, GM1-gangliosidosis,
Fabry disease, Farber disease, Niemann-Pick type C, and at least six different types of
neuronal ceroid-lipofuscinoses64–69. With the support of the examples mentioned,
mitochondrial dynamics and function emerge as key areas of research in the context of
deciphering the PNS disease in MLD.
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Figure 1.3 Hypothetical cascade of events in LSD diseases.
Modified from Platt F.M. et al. 2012. 111
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1.5

Rationale, Objective, and Hypotheses

Despite extensive studies, a major deterrent for developing a viable treatment for MLD
remains due to the lack of in depth understanding of the molecular factors involved in
disease pathogenesis and progression in both the CNS and PNS. Our laboratory has
previously demonstrated that sulfatide directly promotes apoptosis in primary neural cells
isolated from cerebellar tissue of the ARSA-/- mouse (referred to in remaining sections as
ARSA knockout [ARSA-KO] mouse). However, the effects of sulfatide in cells pertaining
to the PNS were not examined. The slow and progressive accumulation of sulfatide,
resultant demyelination and peripheral neuropathy in the aging ARSA-KO mouse model
suggests there might be redundancy in ARSA activity in mice, and that the endogenous
rate of sulfatide synthesis is not enough to contribute significantly to a more aggressive
phenotype2,70. To address this, researchers generated a different transgenic ARSA-KO
mouse model that also overexpresses galctose-3-O-sulfotransferase-1 (sulfatidesynthesizing)71. This mouse model presented with more aggressive CNS and PNS
phenotypes, demonstrated through reduced nerve conduction velocities in the peripheral
nerves, indicative of peripheral neuropathy. However, a concern with this mouse model
was the lack of clarity regarding the more severe phenotype being resultant of the increased
storage or increases in sulfatide levels impacting the signal transduction on the plasma
membrane in Schwann cells. This is one of the primary reasons why, subsequent work in
MLD has been conducted in the ARSA-KO mouse model instead.
As discussed earlier, sulfatide participates in different capacities in Schwann cells and
oligodendrocytes. Recognizing the similarities and differences in the impact sulfatide
might have on different cell types is integral to developing both a clearer understanding of
the disease and appropriate treatment options. Additionally, the increasing prevalence of
mitochondrial and other cellular abnormalities in various neurodegenerative and metabolic
diseases highlights a need to investigate the potential contribution of these seemingly
secondary factors in the disease progression and clinical manifestation of MLD-associated
peripheral neuropathy.
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1.5.1

Objective

To characterize the mitochondrial morphology, cytokine secretion and phagocytic
responses in PNS-associated, MLD cells.

1.5.2

Hypotheses

1. Acute in vitro accumulation of sulfatide in Schwann cells and MSC-derived cells from
ARSA-KO will result in mitochondrial dysfunction.
2. The in vitro accumulation of sulfatide in Schwann cells and MSC-derived cells from
ARSA-KO mice will result in disrupted cellular functions prior to lysosomal-induced
autophagy.

1.5.3

Specific Questions

1. Does sulfatide accumulation impact murine Schwann cell viability?
2. Does sulfatide accumulation impact mitochondrial function and/or morphology?
3. Does sulfatide accumulation impact different Schwann cell functions, with a focus on
phagocytic ability and secretion of cytokines?
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Materials and Methods
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2.1
2.1.1

Cell Cultures
Human Fibroblast Cultures

Fibroblasts from MLD patients and age-matched controls were obtained from the
Biochemical Genetics Laboratory (London Health Sciences Center, London, ON, CA).
Three MLD-patient lines and their respective age- and storage-matched unaffected lines
were used for experiments in this study. All lines were cultured under sterile conditions, in
Dulbecco's Modified Eagle Medium/Nutrient Mixture F-12 (DMEM/F-12; Gibco Cat. No.
11320033) containing 10% fetal bovine serum (FBS). Cells were maintained at 37°C, 5%
CO2 in a humidified incubator with media changes every 72 hours.

2.1.2

Primary Compact Bone-derived Mesenchymal Stromal Cell
Cultures

Mouse mesenchymal stromal cells (MSCs) were isolated from the pooled (n=4) compact
bones (femur and tibia) of one-month-old wildtype (WT) C57BL/6 (referred to in
remaining sections as “ARSA-WT” mouse) and ARSA-/- knockout (ARSA-KO) mice on a
C57BL/6 background. Cells were isolated and cultured as described previously,72 with the
following modifications. Briefly, ARSA-WT and ARSA-KO mice were euthanized in a
carbon dioxide (CO2) gas chamber, following protocols approved by the Western Animal
Use Subcommittee (Western University, London ON, CA) and the Canadian Council on
Animal Care (CCAC). Femora and tibiae from both legs on each mouse were dissected and
promptly placed into EasySep Buffer (Stemcell Technologies, Cambridge, UK, Cat. No.
20144) containing 1% penicillin/streptomycin on ice. The bones remained on ice while
being transported back to the laboratory. Inside a biological safety cabinet (BSC), bones
were cleaned and flushed of any remaining connective tissue and bone marrow. Bones were
cut into smaller fragments (approximately 1-5 mm in length, using sterile bone-cutting
scissors) and then incubated in collagenase B (Millipore Sigma-Aldrich, Darmstadt,
Germany, Cat. No. 110888807001) solution for approximately 5 minutes at room
temperature. Next, an additional 10-20 mL of collagenase B solution was added to the
fragmented bones and incubated at 37°C for approximate 1-1.5 hours on a rocking platform
(Incu-shaker Mini, Benchmark Scientific, Edison, NJ, USA Cat. No. H1000-M) at 200
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rpm. The cell suspension was passed through a 40μm filter, centrifuged at 300 x g for 10
mins at 4°C and resuspended in fresh Mesencult Media (Stemcell Technologies,
Cambridge, UK, Cat. No. 05513) supplemented with 2 mM L-glutamine (Stemcell
Technologies, Cambridge, UK, Cat. No. 07100). Nucleated cells were counted using 3%
acetic acid with methylene blue (Stemcell Technologies, Cat. No. 07060) and colonyforming (CFU) assays were set up according to previously described protocol72. Remaining
cells were plated into T-75 flasks and cultured under low-oxygen (10% O2), 5% CO2 at
37°C in a humidified incubator.

2.1.3

Mouse Schwann Cell Cultures

Primary Schwann cells isolated from the sciatic nerves of postnatal day 8 C57BL/6 mice
were purchased from ScienCell Research Laboratories (Cat. No. M1700-57). Prior to
shipment, cells were characterized by immunofluorescence for S100, glial fibrillary acidic
protein (GFAP) and cluster of differentiation 90 (CD90) and were provided with a
company guarantee of 5 passages under specified conditions. Cells were cultured according
to manufacturer’s specific protocols73 on poly-D-lysine coated culture-ware, in Schwann
Cell Media (SCM, ScienCell Technologies, Cat. No. 1701) supplemented with 1%
Penicillin/Streptomycin (P/S), 25% FBS and 10% Schwann cell growth supplement
(SCGS, ScienCell Technologies, Cat. No. 1752). Cells were maintained at 5% CO2, 37°C
in a humidified incubator with media changes every 48 hours.

2.1.4

MSC-derived Cell Cultures

To evaluate impacts of abnormal sulfatide accumulation in the PNS, we cultured compact
bone derived MSCs from ARSA-WT and ARSA-KO mice in SCM, differentiating them
into cells that morphologically resembled Schwann cells. After MSCs reached
approximately 80-85% confluency, we switched the media to the commercially available
SCM (ScienCell Technologies, Cat. No. 1701). Cells were maintained in SCM for the
remainder of time required for experiments under low oxygen (10% O2), 5% CO2 at 37°C
in a humidified incubator. Media changes were made every 48 hours. Though the cell
cultures, maintained in SCM showed visible morphological changes, given the absence of
rigorous functional testing, they are still considered MSCs.
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2.2

MSC Characterization

The Mesenchymal and Tissue Stem Cell Committee of the International Society of Cell
and Gene Therapy (ISCT) requires that all human MSCs need to be satisfy the following
criteria74: 1) plastic-adherence; 2) MSCs must positively express specific markers (CD105,
CD73 and CD90) and negatively express another set of markers (CD45, CD34, CD14 or
CD11b, CD79α or CD19 and HLD-DR); 3) MSCs must demonstrate in vitro multipotency
(differentiate into osteoblasts, adipocytes and chondroblasts). A similar criterion has been
used by researchers75,76 to characterize MSCs isolated from murine models, with the main
difference being the specific marker expression analyzed. Positive marker expression of
CD106, stem cell antigen-1 (Sca-1) and negative expression of CD45, in addition to plastic
adherence and demonstrated multipotent differentiation are accepted criteria for MSCs
based on literature review.
All MSCs were tested for surface marker expression of CD106, Sca-1 and CD45 by flow
cytometry, in addition to satisfying other recommended criterion listed above. Cells
staining was done as described previously77, following the “no-wash” protocol and 2%
paraformaldehyde (PFA) fixation. Samples were stored at 4°C overnight and transported
to the flow cytometry facility (London Regional Flow Cytometry Facility, Robarts
Research Institute) on ice. Data were acquired using a Beckton Dickinson LSRII flow
cytometer. Data analysis was performed using FlowJo v10.1 (FlowJo LLC, Ashland,
Oregon).

2.2.1

Adipocyte Differentiation

The differentiation potential of MSCs into adipocytes was tested using the Mouse
Mesencult Adipogenic Differentiation Kit (Stemcell Technologies, Cat. No. 00507), to
satisfy listed criterion (Section 2.2), as previously described78. Briefly, MSCs (passage 1)
from ARSA-WT and ARSA-KO cultures were plated at a density of approximately 1-1.3
x104 cells/cm2 and maintained under low oxygen conditions (10% O2), 5% CO2 at 37°C in
a humidified incubator for two days. Following which, cells were maintained in Mesencult
Adipogenic Differentiation Medium (Stemcell Technologies, Cat. No. 05509), with media
changes every 3 days for a duration of 8-10 days. Differentiation was confirmed by
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fluorescent labeling of lipid droplets with 4,4-difluoro-5,7-dimethyl-4-bora-3a,4a-diaza-sindacene-3-hexadecanoic acid (BODIPYTM FL C1679, Invitrogen, Cat. No. D3821).
BODIPY C16 is an intrinsically lipophilic dye that has been used to visualize lipid
aggregation and droplets39,80,81. Cells were then washed with 300μL of Dulbecco's
phosphate-buffered saline (DPBS), twice prior to imaging in 200μL of serum-free, phenol
red-free DMEM/F12 (Gibco Cat. No. 11320033).

2.2.2

Colony Forming Assay

MSCs have previously been referred to as fibroblastoid colony-forming cells due to the
generation of colonies when plated at low densities, in addition to their plastic
adherence72,82. The use of CFU assays has since been used a measure of cell preparation
quality, with the efficiency of colony formation being proportional to quality. CFU-assays
were set up, as described72. Colonies were fixed in 2% PFA and subsequently stained with
0.5% crystal violet as described83. Wells were imaged using both a Nikon Eclipse TE2000s and Xiaomi Mi 2 Camera (8MP, f/2.0, 27 mm(wide), AF LED flash, HDP) and
analyzed using ImageJ (National Institutes of Health, Bethesda, Maryland, United States).

2.3

Lipid Solution Preparation

Cells were treated with different concentrations of sulfatide (Matreya, PA, USA, Cat. No.
1049), galactocerebroside (GalCer; Matreya, PA, USA, Cat. No. 1050). All lipid solutions
were prepared following general lipid solubilization protocol outlined by Sigma Aldrich84.
Briefly, 2 mg of lipids were measured and aliquoted to amber glass vials. Appropriate
amounts of 100% methanol were added to the glass vials, to achieve a concentration of 1
mg/mL. All subsequent concentrations were derived from this stock solution. Stock
solutions were stored at -20°C until use, with parafilm sealed caps.

2.4

Cell Treatments

Cells were maintained under culturing conditions (Section 2.1) until a density of
approximately 1-1.12 x 105 cells/cm2 was reached. Cells were then treated with two lipids
(sulfatide, GalCer), dissolved in methanol as described (Section 2.3) at the following
concentrations: 0 μg/mL, 6.25 μg/mL, 12.5 μg/mL, 25 μg/mL in media. Methanol (vehicle
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control) and media (negative control) were used as controls for every experiment with
matched volumes (µL). The treatments were carried out for the duration of 24 hours, with
different experimental sets being assessed at the following end points: 3 hours, 6 hours, 12
hours, and 24 hours. The specific concentrations and time points used to design the
experiments were based on previous research on primary neural cells isolated from the
ARSA-KO and ARSA-WT mice, that characterized the apoptotic rate in association with
sulfatide accumulation in the ARSA-KO mouse85. All lipid experiments were performed
on cells cultured on poly-D-lysine coated, multi-well black, clear bottom multi-well plates.

2.5

Cell Viability Assays

Cell viability following lipid treatments was assessed using two different assays: Vybrant
MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) cell proliferation
assay and microtiter trypan blue assay. Results from both assays were compared and data
was presented together.

2.5.1

MTT Assay

Following lipid treatments, viability was assessed using the Vybrant MTT Cell
Proliferation Assay as described86. Cell densities were maintained at 1-1.12 x 105 cells/cm2.
Briefly, cells were incubated with approximate 1 mM MTT solution at 37°C for 2.5-4
hours. All but 25μL of labeling solution was removed and 50μL of dimethyl sulfoxide
(DMSO, Sigma Aldrich) was added to each well and mixed well prior to incubation at
37°C for 10 minutes. Cell suspensions were pipetted thoroughly, and the absorbance was
read at 540 nm on a microplate reader (Varioskan 3.01.15, ThermoFisher, UK).

2.5.2

Trypan Blue Assay

Following lipid treatments, cells viability was assessed as previously described87. Briefly,
cells were washed with 300 µL of DPBS, after which they were stained with 0.05% trypan
blue for approximately 15 minutes and lysed with 1% sodium dodecylsulphate (SDS).
Absorbance was spectrophotometrically measured at 590nm on a microplate reader
(Varioskan 3.01.15, ThermoFisher, UK)87.
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2.6
Mitochondrial Membrane Potential and
Morphology
Mitochondrial morphology was visualized, and membrane potential changes were
measured by treating cells with 45 nM MitoTracker Red CMRos (MTR; ThermoFisher,
Cat. No. M7512) prior to lipid treatments for 30 minutes at 37°C. Staining media was
removed and replaced with fresh media. Lipids were subsequently added to the media at
appropriate concentrations. Fluorescence was measured (Ex./Em. 579 nm/ 599 nm) on a
microplate reader (Varioskan 3.01.15, ThermoFisher, UK) and imaged in parallel as
described in subsequent sub-sections. The plate reader measurements and fluorescence
intensity measurements quantified by ImageJ were combined to determine an estimated
value for mitochondrial membrane potential (MMP). Changes in MMP (i.e. the
fluorescence signal intensity) amongst treatment group, in comparison to untreated
controls were reported as relative MMP in subsequent sections.

2.6.1

Live Cell Fluorescence Microscopy Image Acquisition

At appropriate time points following lipid treatments, media from was removed and
discarded. Cells were washed with 200 µL/well DPBS prior to the addition of phenol-red
and FBS-free DMEM media (100 µL/well). Cells were imaged on an inverted epifluorescence Leica DM IRB microscope (Leica Microsystems, Ontario, Canada). Six
random fields of view per well and three wells per treatment group, were acquired at 20x,
40x and 63x magnification using a Nikon Eclipse TE-2000s camera. Images were initially
organized in Openlab imaging software (Perkin Elmer, Ontario, Canada), following
analyses in ImageJ and MATLAB-based tools.

2.6.2

Mitochondrial Image Quantification

All images were imported into ImageJ2/FIJI v1.x (National Institutes of Health, Bethesda,
Maryland, United States). Images were analyzed in three steps: manual grading, semiautomated assessment, and automated morphology characterization. Manual grading
involved categorizing mitochondria into one of three groups (hyperfused; intermediate;
fragmented) in at least 30 cells for each treatment group. Manual quantification was not
reported in this document as it was used to ensure consistent findings between the semi-

22

automated and automated analyses. A semi-automated ImageJ plugin, called
Mitochondrial Network Analysis (MiNa) was used to analyze the mitochondrial networks
and morphology as described88,89. Briefly, the grayscale 8-bit image is converted to a binary
image through automated thresholding (Otsu) and skeletonized (using another plugin
named Skeletonize). The wireframe generated by the skeleton enabled categorization of
pixels into different groups associated with a network morphology. MiNa output consists
for mean network size (counts of number of branches per network), fragment length
(average branch lengths) and mitochondrial footprint (total area expressing the
fluorescence signal). The automated analyses were performed in a MATLAB-based tool
called MicroP90. The output provided includes identification of mitochondrial subtypes (six
different subtypes: small globules, swollen globules, linear tubules, twisted tubules,
branched tubules, and loops/donuts), including area associated with each subtype. In this
study, three main subtypes have been reported: small globules, swollen globules and
“tubules and loops” (aggregated group). The following MicroP subtypes were aggregated
into the “tubules and loops” subgroup reported: “linear tubules”, “twisted tubules”,
“branched tubules” and “loops/donuts”.

2.7

ELISA

Following lipid treatments, at appropriate time points, cell supernatants were collected into
0.5 mL microcentrifuge tubes, centrifuged at 1000 x g for 10 minutes at 4°C and stored at
-80°C until assayed. Secreted TNF-α and IL-1β levels were measured using the Mouse
TNF alpha Uncoated ELISA kit (Invitrogen, Cat. No. 88-7324) and the Mouse IL-1 beta
Uncoated ELISA kit (Invitrogen, Cat. No. 88-7013) according to the manufacturer’s
instructions91,92. Briefly, frozen media samples were thawed at 4°C, gently vortexed and
aliquoted into respective wells. All samples were measured in triplicate and averaged prior
to analyses. Measurements were given in pg/mL.

2.8

Phagocytosis Assay

Phagocytosis is a critical function for Schwann cells and MSCs in the PNS. The phagocytic
ability of sulfatide treated cells was analyzed using the Phagocytosis Assay Kit (Cayman
Chemical Company) following the recommend instructions93. Briefly, cells were treated
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with either sulfatide, GalCer, methanol or media as described earlier. Rabbit IgGfluorescein isothiocyanate (FITC) latex beads (0.1µm) were added to treated cells to be
engulfed. The FITC fluorescence (Ex./Em. 485 nm/ 535 nm) was measured on a microplate
reader (Varioskan 3.01.15, ThermoFisher, UK). Net experimental readings were values
(fluorescent values) were representative of phagocytic response to treatments. Net positive
readings were representative of phagocytic response under normal physiological
conditions (control). Net phagocytic effect was calculated using the following equation:
Equation 1. Phagocytic Effect (%)
% 𝐸𝑓𝑓𝑒𝑐𝑡 =

𝑁𝑒𝑡 𝐸𝑥𝑝𝑒𝑟𝑖𝑚𝑒𝑛𝑡𝑎𝑙 𝑅𝑒𝑎𝑑𝑖𝑛𝑔
x 100%
𝑁𝑒𝑡 𝑃𝑜𝑠𝑖𝑡𝑖𝑣𝑒 𝑅𝑒𝑎𝑑𝑖𝑛𝑔

Equation 2. Relative Phagocytic Effect
𝑅𝑒𝑙𝑎𝑡𝑖𝑣𝑒 𝑃ℎ𝑎𝑔𝑜𝑐𝑦𝑡𝑖𝑐 𝐸𝑓𝑓𝑒𝑐𝑡 =

𝐸𝑥𝑝𝑒𝑟𝑖𝑚𝑒𝑛𝑡𝑎𝑙 𝐸𝑓𝑓𝑒𝑐𝑡
𝐶𝑜𝑛𝑡𝑟𝑜𝑙 𝐸𝑓𝑓𝑒𝑐𝑡

Following calculation of phagocytic effect, the relative change in effect between the treated
and control groups was reported. In parallel, cells incubated with beads and counterstained
with 40 μM Hoechst 33342 (ThermoFisher, Cat. No. H3570) for 10 minutes at 37°C.
Following two washes with 300 μL of DPBS, cells were imaged at 20X and 40X
magnification on an inverted fluorescence Leica DM IRB microscope (Leica
Microsystems, Ontario, Canada). Images were analyzed in ImageJ (National Institutes of
Health, Bethesda, Maryland, United States).

2.9

Statistical Analyses

Statistical analyses were conducted, and graphs were generated using GraphPad Prism v.
500 (San Diego, CA, USA). MSC culture monitoring and colony formation assays were
analyzed using unpaired t-tests, correcting for multiple comparisons using the Holm-Sidak
method. Fluorescence measurements in adipocyte differentiation quantification and
surface marker expression were also analyzed using unpaired t-tests. Relative changes in
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the mitochondrial morphology (subtypes) for treated cells were determined in relation to
control, untreated cells. Similar approach was used for assessing phagocytic changes as
described (Section 2.8). Phagocytic effect changes were analyzed using two-tailed MannWhitney U tests. Differences in cell viability, mitochondrial morphology, and ELISAs
were analyzed using two-way analysis of variance (ANOVA) followed by Bonferroni’s
multiple comparison test to measure differences between groups and Tukey’s multiple
comparison test to measure differences within groups. Statistical significance was set at
p<0.05 for all analyses.
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Chapter 3

3

Results
3.1
Developing and characterizing a murine MLD in
vitro cell model

Genotyping was done previously in our laboratory (not reported in this document), to
confirm complete deletion of the ARSA gene in the ARSA-KO mouse. MSCs were isolated
and cultured from ARSA-WT and ARSA-KO mice. The average total live cell population
dissociated from the pooled (n=4) compact bones from both ARSA-WT and ARSA-KO
mice was approximately 7.125-8.3 x 106 cells. The nucleated cell counts were determined
by manual counting with 3% acetic acid with methylene blue, prior to plating. Initial cell
populations (P0) were visibly heterogenous (Figure 3.1), with subsequent passages and
culture in Mesencult media selecting for an MSC population. CFU assays were performed
at the time of culture. No significant differences in colony formation were observed
between the ARSA-WT and ARSA-KO cell populations (Figure 3.2).
Cultured cells were characterized as MSCs based following the criteria of the ISCS
(Section 2.2). All cells were plastic adherent, determined by passaging of cells. MSCs were
successfully differentiated into adipocytes (Figure 3.3). Lastly, cells were analyzed for
positive expression of surface cell markers, CD106, Sca-1 and negative expression of
CD45 (Figure 3.3). Viable cells were over 90% positive for CD106 and Sca-1 and less
than 5% positive for CD45.
To generate a reliable in vitro model, useful for understanding the PNS disease in MLD,
we chose to differentiate MSCs into cells resembling Schwann cells. This was done
through exposure of MSCs to SCM (Stem Cell Technologies), containing propriety
mixture of Schwann cell-selective growth factors 94. Morphological changes in MSCs were
monitored (Supplementary Figure 2) and showed a distinct change in cell size and shape.
Cells cultured under SCM were visibly elongated and appeared to form long processes that
extended to connect with neighboring cells. These cells lines will be referred to as cbMSCARSA-WT and cbMSC-ARSA-KO subsequently in this document.
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To ensure the cbMSC-ARSA-KO cell line demonstrates sulfatide storage, as expected in
MLD, we treated the cells with N-Dodecanoyl-NBD-sulfatide (NBD-labelled sulfatide;
Matreya) for a duration of 48 hours (Figure 3.4). As seen in the figure, the cbMSC-ARSAKO cells showed a distinct accumulation of the fluorescently labelled lipid in a perinuclear
manner, corresponding with the localization of lysosomes. Whereas cbMSC-ARSA-WT
cells showed very little fluorescence, indicating that the loaded sulfatide was metabolized
over the 48-hour time period.
We were able to successfully establish two MSC-derived cell lines from our mouse colony
that can be used for subsequent in vitro studies relating to different aspects of the PNSdisease in MLD.
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Figure 3.1 Primary mesenchymal stroma1 cell culture populations. Cell populations
became more homogenous over passages, while cultured in MSC-selective Mesencult media.
Cells pictured on the top row were cultured from compact bones (femur and tibia, n=4) of
ARSA-WT mice (cbMSC-ARSA-WT), aged ≤ 1 month. Cells pictured on the bottom row
were cultured from compact bones (femur and tibia, n=4) ARSA-KO mice (cbMSC-ARSAKO), aged ≤ 1 month. Cells were imaged from 12 different fields of view per passage for
monitoring purposes. The cells were categorized into 3 groups based on morphology:
fibroblast-like, spindle-shaped and miscellaneous. Scale bar in red is 5μm. Scale bar in black
is 10μm.
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Figure 3.2 Cells isolated from murine compact bone demonstrated stem cell
character. Freshly isolated murine cells were seeded at low densities in triplicate, in 12well plates and evaluated for colony formation after 15 days. (A) Clonal colonies formed
by colony forming units, were observed by crystal violet staining. (B) Relative colonies
observed at each of the 4 seeding densities between the ARSA-WT and ARSA-KO
cultures. (C) Relative colony size observed between ARSA-WT and ARSA-KO cultures.
(C) Relative colony area between ARSA-WT and ARSA-KO cultures. No significant
differences were seen in colony formation between the ARSA-WT and ARSA-KO
cultures. Data are expressed as mean ± SEM and were analyzed using unpaired t-tests,
correcting for multiple comparisons using the Holm-Sidak method.

31

32

Figure 3.3 MSC adipocyte differentiation. MSCs were differentiated into adipocytes as
per the characterization criteria. Adipocytes were identified by staining with fluorescent
BODIPY-C16. (A) Representative images of cbMSC-ARSA-WT and cbMSC-ARSA-KO
cells differentiated into adipocytes at passage 3 (P3). Normalized fluorescent intensity of
BODIPY-labelled adipocytes and undifferentiated MSCs is also provided. Data are
expressed as mean ± SEM and were analyzed using unpaired t-tests. Both cbMSC-ARSAKO and cbMSC-ARSA-WT cell populations treated with adipocyte differentiation media
displayed significantly higher (**** p<0.0001) uptake of BODIPY-C16 compared to their
untreated controls. Scale bar is 5 μm. (B) Cells were also characterized as MSCs based on
expression of surface markers CD106 and Sca-1 populations became more homogenous
over passages, while cultured in MSC-selective Mesencult media. (A) Representative
individual histograms for markers CD106, Sca-1 and CD45 for both cbMSC-ARSA-WT
and cbMSC-ARSA-KO populations.
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Figure 3.4 MSCs isolated from ARSA-KO mice exhibit accumulation of NBD-labelled
sulfatide in perinuclear, lysosomal distribution. cbMSC-ARSA-WT and cbMSCARSA-KO cells were exposed to 10nmoles of NBD-sulfatide for 48 hours under hypoxic
conditions. Cells were stained with 2.5 μg/mL of Hoescht 33342 for 20 minutes, prior to
imaging. Images were taken at 63X magnification, at 500ms exposure time. Scale bar is 5
μm.
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3.2

Does sulfatide decrease cell viability?

Cells with deficient ARSA enzyme activity demonstrate intralysosomal storage of the lipid,
with prolonged accumulation resulting in cell death. To test the acute impact of exogenous
sulfatide on cell viability, the following cell types were assessed: murine Schwann cells
(WT); cbMSC-ARSA-KO and cbMSC-ARSA-WT cell lines; human MLD and WT
fibroblast cell lines. There are four different sulfatide treatment groups discussed
subsequently (S1: 0 µg/mL; S2: 6.25 µg/mL; S3: 12.5 µg/mL; S4: 25 µg/mL). In parallel,
cells were treated with GalCer, used here as a lipid control and methanol as a vehicle
control.
The cbMSC-ARSA-WT and cbMSC-ARSA-KO cell cultures were maintained under
hypoxic conditions for approximately two days prior to the lipid treatments. Cell viability
was assessed at four different time points (3, 6, 12, 24 hours) following lipid treatments
(Figure 3.5). No significant differences in viability were identified between cbMSCARSA-WT and cbMSC-ARSA-KO cells and within each respective group, across all
treatment groups and time points. GalCer and methanol control treatments resulted in
similar non-significant changes in viability.
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Figure 3.5 Murine MSCs do not exhibit decrease in viability up to 24 hours after
exposure to sulfatide treatments. cbMSC-ARSA-WT and cbMSC-ARSA-KO cell
cultures were treated with 4 different sulfatide concentrations (0, 6.25, 12.5 and 25
μg/mL) for a period of 3, 6, 12 and 24 hours in parallel. Cell viability was assessed
spectrophotometrically with a trypan blue microtiter assay, at 590 nm on a microplate
reader (Varioskan 3.01.15, ThermoFisher, UK). Percentage viability was calculated
relative to the control, non-treated wells. Data are expressed as mean ± SEM and
analyzed using two-way ANOVA. No significant changes were identified at any time
point or between treatment group.
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In order to assess whether sulfatide exposure might impact cell viability of bona-fide
murine Schwann cells, we repeated the same experiments with commercially bought
primary Schwann cells (Figure 3.6). Like cbMSC-ARSA-WT cells, no significant
differences were noted across the different concentrations and different time points. GalCer
and methanol control treatments resulted in similar non-significant changes in viability.
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Figure 3.6 Sulfatide and GalCer treatments do not decrease cell viability in murine Schwann cells. WT-Schwann cells
were treated with sulfatide and GalCer (0, 6.25, 12.5 and 25 μg/mL) for a period of 3, 6, 12 and 24 hours in parallel. Cell
viability was assessed spectrophotometrically with a trypan blue microtiter assay, at 590nm on a microplate reader (Varioskan
3.01.15, ThermoFisher, UK). Percentage viability was calculated relative to the control, non-treated wells. Data are expressed
as mean ± SEM and analyzed using two-way ANOVA. No significant changes were identified at any time point or between
treatment group.
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Patient-derived fibroblasts were investigated as they are the only in vitro model directly
linked to the human disease. From experience, the growth rates of the MLD cells (human)
are slightly lower than their unaffected, age and storage matched control cell lines. Under
normal cell culture conditions, no significant decrease in viability was noted in the patientderived cells previously. Cell viability assessments following lipid treatments in human
fibroblasts (Figure 3.7) also yielded non-significant results.

The main finding from these experiments was that sulfatide treatments (0-25µg/mL) did
not decrease cell viability in cbMSC-ARSA-KO, Schwann (WT), and patient-derived cells
within a 24-hour period of exposure. Despite the clear storage of the lipid, no decrease in
cell viability was seen in the MLD cells.
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Figure 3.7 Human MLD do not exhibit decrease in viability despite sulfatide treatment. Human fibroblasts cultured from
MLD-affected (iMLD) and unaffected patients (Control) were treated with sulfatide (0, 6.25, 12.5 and 25 μg/mL) for a period
of 6, 12 and 24 hours in parallel. Cell viability was assessed spectrophotometrically with a trypan blue microtiter assay, at 590nm
on a microplate reader (Varioskan 3.01.15, ThermoFisher, UK). Percentage viability was calculated relative to the control, nontreated wells. Data are expressed as mean ± SEM and analyzed using two-way ANOVA. No significant changes were identified
at any time point or between treatment group.
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3.3
Analysis of mitochondrial morphology after
sulfatide exposure
Clinical variability regarding degree of demyelination and peripheral neuropathy in MLD
have raised questions of presence of alternative pathogenic cascades, in addition to storage
of sulfatide inclusion bodies. Researchers have described abnormalities in the ER and
mitochondria in Schwann cells of disease-affected cells95,96. To examine the mitochondrial
abnormalities, morphological changes were characterized in the following cell types:
murine Schwann cells (WT), cbMSC-ARSA-WT and cbMSC-ARSA-KO cultures, and
human MLD and WT fibroblasts over the course of 24 hours after exposure to sulfatide.
Schwann cells are energetically demanding cells, illustrating the need for proper
mitochondrial function. In many mitochondrial diseases, neurological functions are greatly
impacted. To establish an understanding of the dynamic expectations of mitochondrial
compensation to sulfatide under non-disease conditions, murine Schwann cells (WT) were
treated with sulfatide as described earlier (Section 2.4). Mitochondria were imaged and
analyzed at the following time points following sulfatide treatment: 3, 6, 12 and 24-hours.
MiNa analyses (Figure 3.8) demonstrated no differences in MMP and overall
mitochondrial footprint between sulfatide treatment groups across all time points in murine
Schwann cells. At 24-hours, network sizes were higher (p<0.05) in cultures at the higher
sulfatide treatments (12.5 and 25 µg/mL) compared to control cultures. Two-way ANOVA
determined that there were differences with respect to proportion of mitochondrial subtypes
(p<0.0001) and sulfatide concentration (p<0.001). Tukey’s post-hoc analysis returned
significant differences between the sulfatide treatment groups at all time points.
As shown in Figure 3.9, at the 3-hour and 6-hour time points, Schwann cells treated with
sulfatide demonstrated a significant increase in the presence of mitochondria shaped as
swollen globules (associated with fission events, thought to lead to mitophagy), compared
to untreated controls. At the 12-hour time point, the proportion of swollen globules in the
cultures decreased and by the 24-hour time point, all cultures were comparable in terms of
swollen globular structures. At all sulfatide concentrations, the proportion of mitochondria
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characterized as tubules and loops were increased. This morphological subtype group is
associated with fusion events.
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Figure 3.8 Dynamic mitochondrial morphological changes in Schwann cells after
treatment with sulfatide. Separate cell cultures treated with 4 different sulfatide
concentrations (0[S1], 6.25[S2], 12.5[S3] and 25[S4] μg/mL) for a period of 3 [T3], 6 [T6],
12 [T12] and 24 [T24] hours in parallel. (A) Mitochondrial membrane potential (MMP) as
measured by fluorescence signal intensity. (B) Network sizes detected by MiNa tool. (C)
Mitochondrial footprint measured by MiNa. N = 450-1000 mitochondria from 50-75 cells
from each treatment group, over 3-4 independent experiments. Images were taken at 63X
magnification, at 500 ms exposure time. Groups were compared using a two-way ANOVA,
**** p<0.0001 and data are expressed as mean ± SEM.
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Figure 3.9 Dynamic mitochondrial subtypes in Schwann cells after treatment with
sulfatide. (A) Representative images of MitoTracker Red CMXRos staining and MicroP
analysis of Schwann cells after sulfatide treatment. Separate cell cultures treated with 4
different sulfatide concentrations (0[S1], 6.25[S2], 12.5[S3] and 25[S4] μg/mL) for a
period of 3 [T3], 6 [T6], 12 [T12] and 24 [T24] hours in parallel. Mitochondria are
categorized into 6 different subtypes: small globe (blue), large globe (yellow), twisted tube
(orange), donut (red) and branching tube (purple). N = 450-1000 mitochondria from 50575 cells from each treatment group, over 3-4 independent experiments. Images were taken
at 63X magnification, at 500 ms exposure time. Scale bar is 5 μm. Schwann cells displayed
larger increase in swollen and fragmented mitochondria at the higher sulfatide treatments
at the 3- and 6-hour marks. With time, at the 24 hours mitochondrial structures returned to
similar proportions seen in untreated cells. Groups were compared using a two-way
ANOVA, **** p<0.0001 and data are expressed as mean ± SEM.
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cbMSC-ARSA-WT and cbMSC-ARSA-KO cultures were treated with sulfatide as
described earlier (Section 2.4). Mitochondria were imaged and analyzed at the following
time points following sulfatide treatment: 6, 12 and 24-hours. Treated cbMSC-ARSA-WT
and cbMSC-ARSA-KO cultures at time points T6 (Figure 3.11; 3.12), T12 (Figure 3.13;
3.14), T24 (Figure 3.15; 3.16) were subjected to the same image analysis.
Untreated mitochondrial subtype information demonstrates no differences (Figure 3.10)
between cbMSC-ARSA-WT and cbMSC-ARSA-KO cultures. Two-way ANOVA
determined that at 6 hours (T6; Figure 3.11), mitochondrial footprint was increased
(p<0.05) in cbMSC-ARSA-WT compared to untreated control cultures and compared to
cbMSC-ARSA-KO cultures. No differences in MMP and network sizes were found
between cbMSC-ARSA-WT and cbMSC-ARSA-KO cultures across all sulfatide
concentrations. As shown in Figure 3.12, MicroP analyses demonstrated increased
(p<0.0001) swollen globular structures in both cbMSC-ARSA-WT and cbMSC-ARSAKO cultures compared to untreated controls. Swollen globular structures were increased
(p<0.0001) and small globular structures (p<0.0001) were decreased in cbMSC-ARSAKO cultures compared to cbMSC-ARSA-WT cultures at all concentrations.
At 12 hours (Figure 3.13), mitochondrial footprint was increased (p<0.05) in cbMSCARSA-WT cultures compared to cbMSC-ARSA-KO. No differences in mitochondrial
footprint, network sizes and MMP were found between the cbMSC-ARSA-WT and
cbMSC-ARSA-KO cultures across all other concentration groups. MicroP analyses
(Figure 3.14) demonstrated increased (p<0.0001) swollen globular structures in cbMSCARSA-KO cultures at all concentrations compared to cbMSC-ARSA-WT and untreated
controls. There were increased (p<0.0001) small globular structures at all concentrations
in cbMSC-ARSA-WT cultures compared to control.
At 24 hours (Figure 3.15), no differences were found in the MMP, network sizes and
mitochondrial footprint between the cbMSC-ARSA-KO and cbMSC-ARSA-WT cultures,
across all sulfatide treatments. Like previous time points (Figure 3.16), cbMSC-ARSAKO cultures demonstrated increased (p<0.0001) small globular and swollen globular
structures compared to cbMSC-ARSA-WT and untreated controls. However, unlike other

50

time points, mitochondrial subtype composition in cbMSC-ARSA-WT cultures were
comparable to untreated controls.
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Figure 3.10 Mitochondria are structurally heterogenous under normal culturing
conditions. (A) Representative images of MitoTracker Red CMXRos staining and MicroP
analysis of cbMSC-ARSA-KO and cbMSC-ARSA-WT cells under normal culturing
conditions. Mitochondria are categorized into 6 different subtypes: small globe (blue),
large globe (yellow), twisted tube (orange), donut (red) and branching tube (purple). N =
450-1000 mitochondria from 50 cells per genotype, over 3-4 independent experiments.
Images were taken at 63X magnification, at 500ms exposure time. Scale bar is 5 μm. At
increasing concentrations of sulfatide exposure, cbMSC-ARSA-KO cells displayed higher
volume of mitochondria compared to cbMSC-ARSA-WT cells. Groups were compared
using a two-way ANOVA, **** p<0.0001 and data are expressed as mean ± SEM.
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Figure 3.11 Mitochondrial morphology changes 6-hours after sulfatide treatments.
Separate cbMSC-ARSA-KO and cbMSC-ARSA-WT cultures were treated with 4 different
sulfatide concentrations (0[Control], 6.25[S2], 12.5[S3] and 25[S4] μg/mL) for a period of
6 [T6] hours in parallel. (A) Mitochondrial membrane potential (MMP) as measured by
fluorescence signal intensity. (B) Network sizes detected by MiNa tool. (C) Mitochondrial
footprint measured by MiNa. N = 450-1000 mitochondria from 30-50 cells from each
treatment group, over 3-4 independent experiments. Images were taken at 63X
magnification, at 500 ms exposure time. Groups were compared using a two-way ANOVA,
**** p<0.0001 and data are expressed as mean ± SEM.
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Figure 3.12 Mitochondrial subtypes 6-hours after sulfatide treatments. Separate
cbMSC-ARSA-KO and cbMSC-ARSA-WT cultures treated with 4 different sulfatide
concentrations (0[Control], 6.25[S2], 12.5[S3] and 25[S4] μg/mL) for a period of 6 [T6]
hours in parallel. (A) Representative images of MitoTracker Red CMXRos staining and
MicroP analysis of cells after sulfatide treatment. Mitochondria are categorized into 6
different subtypes: small globe (blue), large globe (yellow), twisted tube (orange), donut
(red) and branching tube (purple). cbMSC-ARSA-KO and cbMSC-ARSA-WT
mitochondria display larger distribution of small globular and swollen globular structures
compared to untreated controls. At the highest concentration, treated cells display larger
proportion of tubular structures indicative of longer, more networked mitochondria. N =
450-1000 mitochondria from 30-50 cells from each treatment group, over 3-4 independent
experiments. Images were taken at 63X magnification, at 500 ms exposure time. Scale bar
is 5 μm. Groups were compared using a two-way ANOVA, **** p<0.0001 and data are
expressed as mean ± SEM.
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Figure 3.13 Mitochondrial morphology changes 12-hours after sulfatide treatments.
Separate cbMSC-ARSA-KO and cbMSC-ARSA-WT cultures treated with 4 different
sulfatide concentrations (0[Control], 6.25[S2], 12.5[S3] and 25[S4] μg/mL) for a period of
12 [T12] hours in parallel. (A) Mitochondrial membrane potential (MMP) as measured by
fluorescence signal intensity. (B) Network sizes detected by MiNa tool. (C) Mitochondrial
footprint measured by MiNa. N = 450-1000 mitochondria from 30-50 cells from each
treatment group, over 3-4 independent experiments. Images were taken at 63X
magnification, at 500 ms exposure time. Groups were compared using a two-way ANOVA,
**** p<0.0001 and data are expressed as mean ± SEM.
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Figure 3.14 Mitochondrial subtype changes 12-hours after sulfatide treatments.
Separate cbMSC-ARSA-KO and cbMSC-ARSA-WT cultures treated with 4 different
sulfatide concentrations (0[Control], 6.25[S2], 12.5[S3] and 25[S4] μg/mL) for a period of
12 [T12] hours in parallel. (A) Representative images of MitoTracker Red CMXRos
staining and MicroP analysis of cells after sulfatide treatment. Mitochondria are
categorized into 6 different subtypes: small globe (blue), large globe (yellow), twisted tube
(orange), donut (red) and branching tube (purple). cbMSC-ARSA-KO and cbMSC-ARSAWT mitochondria display larger distribution of small globular and swollen globular
structures compared to untreated controls. N = 450-1000 mitochondria from 30-50 cells
from each treatment group, over 3-4 independent experiments. Images were taken at 63X
magnification, at 500 ms exposure time. Scale bar is 5 μm. Groups were compared using a
two-way ANOVA, **** p<0.0001 and data are expressed as mean ± SEM.
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Figure 3.15 Mitochondrial morphology changes 24-hours after sulfatide treatments.
Separate cbMSC-ARSA-KO and cbMSC-ARSA-WT cultures treated with 4 different
sulfatide concentrations (0[Control], 6.25[S2], 12.5[S3] and 25[S4] μg/mL) for a period
of 24 [T24] hours in parallel. (A) Mitochondrial membrane potential (MMP) as measured
by fluorescence signal intensity. (B) Network sizes detected by MiNa tool. (C)
Mitochondrial footprint measured by MiNa. N = 450-1000 mitochondria from 30-50 cells
from each treatment group, over 3-4 independent experiments. Images were taken at 63X
magnification, at 500 ms exposure time. Groups were compared using a two-way
ANOVA, **** p<0.0001 and data are expressed as mean ± SEM.
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Figure 3.16 Mitochondrial subtype changes 24-hours after sulfatide treatments.
Separate cbMSC-ARSA-KO and cbMSC-ARSA-WT cultures treated with 4 different
sulfatide concentrations (0[Control], 6.25[S2], 12.5[S3] and 25[S4] μg/mL) for a period of
24 [T24] hours in parallel. (A) Representative images of cells stained with MitoTracker
Red CMXRos. Mitochondria are categorized into 6 different subtypes: small globe (blue),
large globe (yellow), twisted tube (orange), donut (red) and branching tube (purple). At the
highest sulfatide concentration, cbMSC-ARSA-KO cells exhibited larger proportion of
swollen globular structures compared to untreated and cbMSC-ARSA-WT controls. N =
450-1000 mitochondria from 30-50 cells from each treatment group, over 3-4 independent
experiments. Images were taken at 63X magnification, at 500 ms exposure time. Scale bar
is 5 μm. Groups were compared using a two-way ANOVA, **** p<0.0001 and data are
expressed as mean ± SEM.
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Patient-derived and WT fibroblasts were also treated with the same concentrations of
sulfatide described earlier (Section 2.2). At 6 hours following treatment (Figure 3.17), no
differences were found in mitochondrial footprint, network sizes and MMP between the
MLD and WT fibroblasts. As shown in Figure 3.18, MLD fibroblasts had increased
(p<0.0001) swollen globular structures compared to WT fibroblasts across all
concentrations. MLD fibroblasts also had increased small globular structures at higher
(p<0.0001) sulfatide concentrations compared to WT fibroblasts and untreated controls.
Two-way ANOVA determined no differences were found in mitochondrial footprint,
network sizes and MMP (Figure 3.19) at the 12-hour time point between the MLD and
WT fibroblasts. MLD fibroblasts (Figure 3.20) demonstrated increased (p<0.0001)
swollen globular structures in comparison to WT treated cells, while both cultures were
decreased (p<0.0001) compared to untreated controls. MLD fibroblasts had increased
(p<0.0001) small globular structures across all concentrations.
At 24-hours (Figure 3.21), the mitochondrial footprint was decreased (p<0.05) in MLD
fibroblasts compared to the control cells at the highest sulfatide concentration. No
differences were found in MMP, network size and mitochondrial footprint across other
concentrations. Mitochondrial subtype analyses (Figure 3.22) demonstrated increased
swollen globular (p<0.001) and small globular (p<0.0001) structures in MLD fibroblasts
compared to WT fibroblasts and untreated controls. WT treated cells also demonstrated
increased (p<0.0001) small globular structures at higher sulfatide concentrations compared
to untreated controls.
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Figure 3.17 Mitochondrial morphology 6 hours following sulfatide treatments in
human MLD-affected fibroblasts. Separate WT and iMLD fibroblast cultures were
treated with 4 different sulfatide concentrations (0[Control], 6.25[S2], 12.5[S3] and 25[S4]
μg/mL) for a period of 6 [T6] hours in parallel. (A) No differences were seen in the
mitochondrial structural ratios between the WT-fibs and iMLD-fibs under normal culturing
conditions, without sulfatide treatment. (B) Mitochondrial membrane potential (MMP) as
measured by fluorescence signal intensity. (C) Network sizes detected by MiNa tool. (D)
Mitochondrial footprint measured by MiNa. N = 450-1000 mitochondria from 30-50 cells
from each treatment group, over 3-4 independent experiments. Images were taken at 63X
magnification, at 500 ms exposure time. Groups were compared using a two-way ANOVA,
**** p<0.0001 and data are expressed as mean ± SEM.
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Figure 3.18 Mitochondrial subtypes 6 hours following sulfatide treatments in human
MLD-affected fibroblasts. Separate WT and iMLD fibroblasts treated with 4 different
sulfatide concentrations (0[Control], 6.25[S2], 12.5[S3] and 25[S4] μg/mL) for a period of
6 [T6] hours in parallel. (A) Representative images of MitoTracker Red CMXRos staining
of cells following sulfatide treatment. Mitochondria are categorized into 6 different
subtypes: small globe (blue), large globe (yellow), twisted tube (orange), donut (red) and
branching tube (purple). N = 450-1000 mitochondria from 50 cells per genotype, over 3-4
independent experiments. Images were taken at 63X magnification, at 500 ms exposure
time. Scale bar is 5 μm. At increasing concentrations of sulfatide exposure, iMLD
fibroblasts displayed higher volume of mitochondria compared to WT fibroblasts. Groups
were compared using a two-way ANOVA, **** p<0.0001 and data are expressed as mean
± SEM.
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Figure 3.19 Mitochondrial morphology 12 hours following sulfatide treatments in
human MLD-affected fibroblasts. Separate WT and iMLD fibroblasts treated with 4
different sulfatide concentrations (0[Control], 6.25[S2], 12.5[S3] and 25[S4] μg/mL) for a
period of 12 [T12] hours in parallel. (A) Mitochondrial membrane potential (MMP) as
measured by fluorescence signal intensity. (B) Network sizes detected by MiNa tool. (C)
Mitochondrial footprint measured by MiNa. N = 450-1000 mitochondria from 30-50 cells
from each treatment group, over 3-4 independent experiments. Images were taken at 63X
magnification, at 500 ms exposure time. Groups were compared using a two-way ANOVA,
**** p<0.0001 and data are expressed as mean ± SEM.
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Figure 3.20 Mitochondrial subtypes 12 hours following sulfatide treatments in human
MLD-affected fibroblasts. Separate WT and iMLD fibroblasts treated with 4 different
sulfatide concentrations (0[Control], 6.25[S2], 12.5[S3] and 25[S4] μg/mL) for a period of
12 [T12] hours in parallel. (A) Representative images of MitoTracker Red CMXRos
staining of cells following sulfatide treatment. Mitochondria are categorized into 6
different subtypes: small globe (blue), large globe (yellow), twisted tube (orange), donut
(red) and branching tube (purple). N = 450-1000 mitochondria from 50 cells per genotype,
over 3-4 independent experiments. Images were taken at 63X magnification, at 500 ms
exposure time. Scale bar is 5 μm. At increasing concentrations of sulfatide exposure, iMLD
fibroblasts displayed higher volume of mitochondria compared to WT fibroblasts. Groups
were compared using a two-way ANOVA, **** p<0.0001 and data are expressed as mean
± SEM.
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Figure 3.21 Mitochondrial morphology 24 hours following sulfatide treatments in
human MLD-affected fibroblasts. Separate WT and iMLD fibroblast cultures were
treated with 4 different sulfatide concentrations (0[Control], 6.25[S2], 12.5[S3] and 25[S4]
μg/mL) for a period of 24 [T24] hours in parallel. (A) Mitochondrial membrane potential
(MMP) as measured by fluorescence signal intensity. (B) Network sizes detected by MiNa
tool. (C) Mitochondrial footprint measured by MiNa. N = 450-1000 mitochondria from 3050 cells from each treatment group, over 3-4 independent experiments. Images were taken
at 63X magnification, at 500 ms exposure time. Groups were compared using a two-way
ANOVA, **** p<0.0001 and data are expressed as mean ± SEM.
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Figure 3.22 Mitochondrial subtypes 24 hours following sulfatide treatments in human
MLD-affected fibroblasts. Separate WT and iMLD fibroblast cultures were treated with
4 different sulfatide concentrations (0[Control], 6.25[S2], 12.5[S3] and 25[S4] μg/mL) for
a period of 24 [T24] hours in parallel. (A) Representative images of MitoTracker Red
CMXRos staining and MicroP analysis of cells following sulfatide treatment.
Mitochondria are categorized into 6 different subtypes: small globe (blue), large globe
(yellow), twisted tube (orange), donut (red) and branching tube (purple). N = 450-1000
mitochondria from 50 cells per genotype, over 3-4 independent experiments. Images were
taken at 63X magnification, at 500 ms exposure time. Scale bar is 5 μm. At increasing
concentrations of sulfatide exposure, iMLD fibroblasts displayed higher volume of
mitochondria compared to WT fibroblasts. Groups were compared using a two-way
ANOVA, **** p<0.0001 and data are expressed as mean ± SEM.
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3.4 Determining impact of sulfatide on immune responses of
cells
Presence and severity of peripheral neuropathy seen in patients is variable and not
correlated with level of sulfatide accumulation30. This discrepancy has raised the question
that an alternative immune related pathway might complement the lysosomal disease in
MLD. The ARSA-KO mouse model often used in MLD research also presents with
symptoms associated with peripheral neuropathy at later stages in its life. To explore this
aspect of MLD, we performed a series of phagocytosis assays and ELISAs for two
commonly expressed proinflammatory cytokines, TNF-α and IL-1β on cbMSC-ARSA-KO
and cbMSC-ARSA-WT supernatants following sulfatide treatments. ELISAs (Figure
3.23) performed 12 hours after cbMSC-ARSA-KO cultures were exposed to 12.5 and 25
μg/mL of sulfatide exhibited an increase (p<0.001) in IL-1β secretion compared with
cbMSC-ARSA-WT cultures. At the same time point, TNF-α secretion was increased
(p<0.0001) when exposed to sulfatide concentrations as low as 6.25-25 μg/mL compared
to cbMSC-ARSA-WT cultures. At the 24-hour time point, cbMSC-ARSA-KO cultures
expressed higher TNF-α (p<0.0001) and IL-1β (p<0.0001) levels compared to cbMSCARSA-WT cultures.
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Figure 3.23 Cell supernatant concentrations of IL-1β and TNF-α from sulfatidetreated cbMSC-ARSA-WT and cbMSC-ARSA-KO cell cultures. Separate cell cultures
treated with 4 different sulfatide concentrations (0, 6.25, 12.5 and 25 μg/mL) for a period
of 12 hours and 24 hours in parallel. Cell supernatants were collected and assayed in
triplicate for each treatment group. (A) Representative IL-1β standard curve, plotted with
95% confidence interval. (B) At 12 hours after sulfatide treatment, cbMSC-ARSA-KO
cultures exposed to 12.5 and 25 μg/mL of sulfatide exhibited a significant increase in IL1β secretion compared with cbMSC-ARSA-WT cultures. (C) At 24 hours after sulfatide
treatment, cbMSC-ARSA-KO cultures exposed to 6.25, 12.5 and 25 μg/mL of sulfatide
exhibited a significant increase in IL-1β secretion compared with cbMSC-ARSA-WT
cultures. (D) Representative TNF-α standard curve, plotted with 95% confidence interval.
(E) At 12 hours after sulfatide treatment, KO cultures exposed to 6.25, 12.5 and 25 μg/mL
of sulfatide exhibited a significant increase in TNF-α secretion compared with cbMSCARSA-WT cultures. (F) Similar to treatments assessed at 12 hours, cbMSC-ARSA-KO
cultures at 24 hours after exposure to sulfatide treatments (6.25, 12.5 and 25 μg/mL)
exhibited a significant increase in TNF-α secretion compared with cbMSC-ARSA-WT
cultures. Data are expressed as mean concentration in pg/mL ± SEM, **** p<0.0001.
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Schwann cells and MSCs have been shown to have phagocytic functions, specifically at
injury sites. Given that sulfatide is also an important molecule for cellular membranes,
elevations and/or aberrations in metabolism can negatively impact membrane integrity6,7,11.
In the context of MLD, as part of a proposed pathogenic cascade, improper clearance of
debris from demyelination can potentially cause a cyclical inflammatory state. Phagocytic
assays were performed to assess whether cbMSC-ARSA-KO cells have altered phagocytic
capacity after 3 hours of sulfatide exposure. For each sulfatide treatment group, S1 =
0µg/mL (Figure 3.24) ; S2 = 6.25µg/mL (Figure 3.24 A, B); S3 = 12.5µg/mL (Figure
3.24 C, D); S4=25µg/mL (Figure 3.24 E, F), two-tailed Mann-Whitney U tests were
performed. No significant differences in net phagocytic effect was identified. Though not
quantified in this study, beads appeared to cluster and form larger aggregates more
frequently in cbMSC-ARSA-KO cultures when exposed to lower sulfatide concentrations.
Findings from these experiments suggest that sulfatide treatments (0-25µg/mL)
administered for a short period of 3 hours do not significantly change the cbMSC-ARSAKO cells ability to phagocytize beads. However, the slight decrease in phagocytic effect
observed in cbMSC-ARSA-KO cultures warrants further testing, with higher
concentrations sulfatide and/or longer exposure times.
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Figure 3.24 Phagocytosis of FITC-IgG beads in cbMSC-ARSA-KO and cbMSCARSA-WT cultures remains unaffected by sulfatide treatments. Representative
fluorescence images (63x) of phagocytosis of FITC-IgG beads (0.1μm). Cells were labelled
with 2.5 μg/mL of Hoechst 33342 for 20 minutes, prior to imaging. Quantification of
phagocytotic effect is reported to the right of each image panel, calculated using the
methods described in Section 2. (A) Representative images of FITC-IgG beads for cbMSCARSA-WT and cbMSC-ARSA-KO cells in sulfatide treatment group S1 (6.25μg/mL). (B)
Quantification of relative phagocytic effect in treatment group S1 (Mann-Whitney U=2.0,
P>0.999 two-tailed). (C) Representative images of FITC-IgG beads for cbMSC-ARSAWT and cbMSC-ARSA-KO cells in sulfatide treatment group S2 (12.5μg/mL). (D)
Quantification of relative phagocytic effect in treatment group S2 (Mann-Whitney U=2.0,
P>0.999 two-tailed). (E) Representative images of FITC-IgG beads for cbMSC-ARSAWT and cbMSC-ARSA-KO cells in sulfatide treatment group S3 (25μg/mL). (D)
Quantification of relative phagocytic effect in treatment group S3 (Mann-Whitney U=2.0,
P>0.999 two-tailed). No significant differences were found between control and treatment
groups for either cbMSC-ARSA-KO or cbMSC-ARSA-WT. Scale bar is 50µm.
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Chapter 4

4

Discussion

MLD is a progressive, inherited LSD that results in fatal neurodegeneration in affected
patients. It is a psychosocially taxing condition that has detrimental impacts on affected
individuals and their families. Establishing a viable therapy for this disease could
ameliorate the sufferings of affected individuals and families, as well as reduce the
significant economic burden placed on the healthcare system. Given the variable success
of multiple clinical trials in addressing the peripheral nervous system disease in MLD, it is
important to target investigations into understanding the fundamental cellular pathways
involved in MLD disease progression. This study examined the impact of acute sulfatide
accumulation on mitochondrial morphology, cytokine release and phagocytosis in MLD
murine Schwann and cbMSC-ARSA-KO cell populations. We hypothesized that excess
sulfatide in MLD cells would negatively impact important cellular components and
functions including mitochondria and the cellular immune response. We treated MLD cells
with varying concentrations of sulfatide over the course of 24 hours. The viability,
mitochondrial function, and innate immune response of the cells in response to sulfatide
were characterized. Our experiments contribute three important findings: 1) MLD cells
retained the mitochondrial morphology changes at the 24-hour mark after sulfatide
treatment; 2) sulfatide induces increased secretion of proinflammatory cytokines TNF-α
and IL-1β as early as 12 hours after exposure to high sulfatide levels; 3) all these cellular
changes occur within a 24-hour time period, prior to apoptosis. The subsequent section will
address the objective and all the main findings described in the previous section.

4.1

Utility of MSCs in MLD research

An MSC-derived in vitro MLD model from the ARSA-KO mouse was generated, to study
the effects of sulfatide on non-CNS related cells such as Schwann cells and/or Schwann
cell-like cells. MSCs have been documented76,97,98 to exhibit immunomodulatory effects
and shown to participate in the regulation of wound-healing, immune response, and tissue
homeostasis99–102. As a result, they have been extensively utilized in research studies
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looking at a wide range of disease such as type 1 diabetes mellitus, rheumatoid arthritis,
peripheral neuropathy and neurological diseases such as multiple sclerosis (MS) and
amyotrophic lateral sclerosis (ALS)75,103,104. These qualities make MSCs an intriguing
vehicle, in treating LSDs with known inflammatory involvement. A group102, working with
the Twitcher mouse in Krabbe’s disease (a neurodegenerative LSD) showed a decrease in
multiple inflammatory cytokines and an increase in growth factors after transplantation of
MSCs, which halted the deterioration of myelin. Our laboratory has also worked on using
autologous MSC-based gene therapy to address the enzyme deficiency in the CNS of MLD
mice105. The extensive literature evidence of the multipotency, immunomodularity and
ease of access of MSCs prompted us to generate an in vitro model that can be useful to
study PNS-associated responses to sulfatide exposure. Our characterization results of the
isolated cells confirm a mesenchymal identity and subsequent differentiation in Schwann
cell media aligns with the studies mentioned above. Our results from the sulfatide loading
assay, gene, and enzyme activity data from the cbMSC-ARSA-KO and cbMSC-ARSAWT cells confirm an MLD phenotype.

4.2

Role of Sulfatide in the PNS Disease

Glycolipids such as sulfatide are ubiquitous to cellular and lipid bilayer membranes
throughout the body, including the PNS6,11. As sulfatide is multifunctional and prominent
in bio-membranes, abnormalities in its metabolism can potentially impact various
membrane receptors, transporters, and ion channels. Loss of membrane integrity can in
turn impact other cellular functions such as phagocytosis, mitochondrial and lysosomal
motility, formation, division, and fusion. For the reasons explained in Section 4.1, MSCs
were a good starting point to investigate other cellular mechanisms that might be impacted
in response to increased accumulation of sulfatide in MLD cells. We anticipated that
treatment of PNS-related cells with exogenous sulfatide would display decreases in cell
viability. Our findings did not support our hypothesis of decreased cell viability. We
showed that WT Schwann cells and cbMSC-ARSA-KO and cbMSC-ARSA-WT mice do
not undergo rapid decrease in viability after sulfatide exposure over 24 hours in controlled
culturing conditions. As mentioned, (Section 3.2), the specific concentrations and time
points used to design the experiments were extensions of previous laboratory work
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(Supplementary Figure 3) done on primary neural cells isolated from the ARSA-KO and
ARSA-WT mouse cerebella. In the previous studies, primary neural cells from ARSA-KO
mouse cerebella showed a rapid decrease in viability. We know that sulfatide functions in
different capacities in the CNS and PNS106. The decreased cell viability within three hours,
previously characterized in the ARSA-KO neural cells was attributed to increased presence
and likely storage of sulfatide. Interestingly, Schwann and cbMSC-ARSA-KO cells did not
respond to sulfatide treatments in a similar manner. There are a few possible explanations
for this. First, the role of sulfatide in the PNS cells has been shown to be very different
from its role in CNS-related cells, in that sulfatide promotes Schwann cell maturation in
the PNS while it inhibits oligodendrocyte differentiation in the CNS6,11,106. The cells in the
CNS are heavily immuno-protected as a result of the BBB while the BNB in the PNS is
comparatively less protective107. The response of the CNS-related glia to cellular stress is
also different compared to the PNS108,109. In the context of MLD, cellular stress and
subsequent apoptosis is correlated to demyelination in the CNS4. Whereas the progressive
demyelination in the PNS is variable and can likely be attributed to the regenerative and/or
reprogramming capabilities of Schwann cells. These differences in the regional protection,
functional capabilities and restorative cellular mechanisms might explain the differences
observed in the susceptibility of these different cell types to sulfatide-induced apoptosis.

4.3
Can mitochondrial dysfunction contribute to MLD
pathogenesis?
Through a pigeon-hole perspective, lysosomes serve as a major catabolic center in
nucleated cells and are tightly regulated by several autophagic pathways110,111. The roles
and functions of lysosomes continue to expand beyond being the catabolic centers of the
cell. Their role in cellular energy metabolism is quite intriguing. A prevailing thought is
that lysosomal dysfunction, subsequent accumulation, and improper degradation of lipid
molecules might contribute to irregularities in the lipid membranes of other cellular
organelles including mitochondria. In this vein, mitochondrial function can potentially be
impacted in LSDs such as MLD.
Mitochondria undergo cycles of fusion and fission that are identifiable through specific
morphological changes. Mitochondria undergoing fission have been termed as “punctate”,
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“swollen”, or “fragmented”, while mitochondria undergoing fusion are termed as
“networked”, “elongated tubules”90. Previous studies have demonstrated that specific
regulatory proteins involved in mitochondrial dynamics are correlated with the
morphological subtypes112–114. Our findings suggest that cbMSC-ARSA-KO cells have
increased sensitivity to sulfatide-induced cellular stress. We also saw an overall increased
mitochondrial footprint when cells are stressed with sulfatide treatment. The increase in
mitochondrial volume, observed in both cbMSC-ARSA-WT and cbMSC-ARSA-KO cells
can be attributed to increases in number of mitochondria that appear to be fragmented
and/or swollen. The difference between the cbMSC-ARSA-WT and cbMSC-ARSA-KO
treated cells was that the proportion of swollen and fragmented mitochondria eventually
decreased in the cbMSC-ARSA-WT populations whereas it persisted in the cbMSCARSA-KO populations at the 24-hour mark. MLD cells were also noted to have increased
fragmentation that persisted compared to control cells. Similar findings were confirmed in
the human fibroblast model, where MLD cells demonstrated an increased proportion of
fragmented and punctate mitochondria at the 24-hour time point. Disruption of cellular
homeostasis in healthy cells initially promotes mitochondrial fission. However, the
subsequent increase in fusion enables the cell to restore energetic and environmental
abnormalities, reducing mitophagy115–117. Supporting this, the unaffected cells (WT)
demonstrated an increase and subsequent decrease in fragmentation, suggesting that
mitochondria were able to compensate for the stress in the short term and restore
homeostatic state within 24 hours.
It is important to note that the treatments we administered only demonstrate acute exposure
and are unlikely to be representative of the in vivo disease. Assessing the mitochondrial
morphology in nerve explants, determining mitochondrial membrane potential changes in
live mice and cataloging the expression of known markers such as microtubule-associated
proteins 1A/1B light chain 3B (LC3II; a common autophagy marker), mitofusin-1 (Mfn1),
Opa1 (fusion proteins) and Drp1, mitochondrial fission 1 protein (Fis1; fission proteins) in
the aging KO mouse would contribute a fuller picture of the mitochondrial differences in
MLD.
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4.4
Immunological responses caused by dysfunctional
lysosomes in MLD
The first evaluation of inflammation in MLD patients demonstrated elevations of
cytokines, MCP-1, IL-1Ra, IL-8, MIP-1b and VEGF in the cerebrospinal fluid (CSF)46. To
date, no other studies evaluated the inflammatory state in the ARSA-KO mouse model. We
show increased secretion of TNF-α and IL-1β secretion in cbMSC-ARSA-KO cells,
following sulfatide treatment. Our results support the growing body of research that has
shown that Schwann cells and MSCs are capable of producing and secreting
proinflammatory cytokines such as TNF-α and IL-1β, under in vitro conditions118–120. Both
our findings and the CSF findings46 report elevations in proinflammatory cytokines in
association with intracellular sulfatide storage. Contradicting this, Bovin L.F. et. al.120
showed that in human mononuclear leukocytes, GalCer treatment of lipopolysaccharidestimulated (LPS) cells promoted increased amounts of TNF-α and IL-1β production and
secretion, whereas sulfatide treatment decreased secretion of both cytokines. Their study
suggested that sulfatide and GalCer have differential effects on cytokine production, at the
level of gene expression. Sulfatide, a ligand for L-selectin, has also been discussed as
potentially being anti-inflammatory, in the context of diabetes mellitus121. These studies
have shown that the C16:0 isoform of sulfatide (predominantly localized to β-cells in the
islet of Langerhans) exhibits the anti-inflammatory effect through selectin-mediated
inhibition of various pro-inflammatory cytokines such as IL-1, IL-1β, IL-6 and TNFα121,122. An important takeaway from these studies is the multifunctional and differential
role sulfatide and it varies moieties play across different tissues and disease pathologies.
These studies also raise the question of whether the increases in inflammatory cytokines
documented40,123 in MLD and by extension other LSDs can be attributed to the presence of
the metabolite or are a result of lysosomal and/or other organelle-related dysfunction.
Schwann cells are known to have the capacity to degrade damaged myelin and/or initiate
myelin breakdown as well as initiate macrophage induced phagocytosis in PNS injury sites
such as the demyelinating peripheral nerves seen in MLD124. Thus, the ability of Schwann
cells to phagocytose material is a very important function. Our results suggest that cbMSCARSA-KO cells do not display changes in their ability to phagocytose fluorescent beads
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after exposure to increasing amounts of sulfatide. Studies in other LSDs26,28,45 have shown
impaired lysosomal function, in the form of changes to rate of endocytosis and
phagocytosis, impacts the progressive accumulation of toxic metabolite. Though our
results do not support these findings, an important facet to consider is the short period of
sulfatide exposure we investigated. Treatment with sulfatide likely results in some level of
intracellular storage within the 3-hour time period. Following which, degradation and
removal of the storage material requires the lysosomes to fuse with autophagosomes and
complete the autophagic pathway. It is likely that a longer period of sulfatide exposure can
induce phagocytic changes as a result of more prominent lysosomal dysfunction.
Preliminary studies I have conducted (Supplementary Figure 4), with FITC-labelled E.
coli particles suggested a potential decrease in net phagocytic effect when cells were treated
with sulfatide for 1-3 hours prior to assay. Phagocytosis is an extremely complex process
that requires a series of steps, the first of which involves cargo-driven recognition at the
plasma membrane125. The FITC-labelled IgG beads are recognized through the Fc portion
by Fcγ receptors at the plasma membrane whereas Escherichia coli (E. coli) are thought to
be recognized by a different set of receptors known as Toll-like receptors (TLR)126. This is
interesting because sulfatide has also been shown to act as a glycolipid receptor that
different bacterial strains adhere to at the surface of cells127. In addition to recognition by
the respective receptors, the internalization of cargo is actin-dependent128. Following this,
there are number of downstream pathways implicated that in turn have different cellular
effects. One such effect is the increase in cytosolic Ca2+ in response to the action of one of
the Fcγ receptors (FcγR) in neutrophils. Bengtsson et al.129 showed that following ingestion
of IgG-opsonized particles, neutrophils underwent Ca2+-triggered depolymerization of
their actin cytoskeleton which was suggested to be necessary to enable the fusion of the
phagosome with the lysosome. Given the mitochondrial dysfunction noted in literature and
our findings of abnormalities in the MMP and mitochondrial morphology, assessing the
Ca2+ levels and their impact on the actin cytoskeleton and by extension phagocytic
processes in the MLD cells following sulfatide exposure would be an interesting next step.
At present, further work is required before concluding no impact of sulfatide on
phagocytosis in cbMSC-ARSA-KO cultures.
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4.5

Limitations

This study used three different cell types: murine primary Schwann cells, murine MSCderived cells (cbMSC-ARSA-KO and cbMSC-ARSA-WT) and human fibroblasts (WT
and iMLD). Although several studies76,97,98,130–134 have shown murine and human MSCs
isolated from various regions in the body can be differentiated into Schwann cell-like cells,
very few have conducted functional tests such a nerve conduction velocity studies to show
differentiation of MSCs into specific cells. Therefore, the differentiation of MSCs into
Schwann cells remains controversial. Though we followed the criteria established and
accepted by the research community to characterize the differentiation of MSCs, we did
not conduct rigorous testing of functional changes in the cells to establish the Schwann cell
specific terminal differentiation. As a result, our findings can strictly be applied to cells of
mesenchymal origin. Patient-derived fibroblasts have been useful tools for demonstrating
sulfatide accumulation and designing gene therapy vectors but remain limited in their
ability to contribute to better understanding of the disease.
An important consideration for this and subsequent studies revolves around understanding
and considering the relative metabolic states in different cell types. MSCs (form the
compact bone) in vivo are maintained at low oxygen conditions and skew more towards
reliance on glycolysis to meet bioenergetic needs54,116. Whereas, somatically differentiated
cells, including neural and/or Schwann cells are thought to utilize oxidative
phosphorylation 54. Studies have shown a decrease in mitochondrial DNA, as somatic cells
are reprogrammed into iPSCs, showcasing the metabolic switch from oxidative
phosphorylation to glycolysis116. Most of the work in this study used MSC-derived cultures
to assess mitochondrial function in cells that might be meeting their energetic needs
through glycolytic pathways. This is important when considering the lack of decrease in
cellular viability and more pronounced mitochondrial morphology changes in the cbMSCARSA-KO cultures. Furthermore, the cells in the CNS and PNS are also exposed to
different conditions within the body and might explain the differences in disease
progression.
An ideal in vitro model to study the PNS disease in MLD would include Schwann cells
from patients and age-matched, unaffected individuals (control). However, given the
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invasive and clinically unsubstantiated reasoning for collection of the specimen, this is not
a feasible task. The collection of tissue for culture from autopsy is unlikely given the rarity
of the disease, the time-sensitivity involved in tissue collection and the wishes of the patient
and/or family. The next best choice centers around use of induced pluripotent cell (iPSCs)
models, which have recently become more accessible. The iPSC models provide a
potentially powerful tool to deciphering more intricate pathological mechanisms in future
studies.
As part of the mitochondrial analyses, we discussed the relative mitochondrial membrane
potential (MMP) findings in the different treatment groups. Traditionally, MMP is
fluorescently measured with several different lipophilic cationic dyes such as tetramethyl
rhodamine

methyl

(TMRM),

dihexyloxacarbocyanine

iodide

ethyl

(TMRE)

(DiOC6(3))

ester,
and

Rhodamine

123,

3,3’-

5,5’,6,6’-tetrachloro-1,1’,3,3’-

tetraethylbenzimidazolylcarbocyanine iodide (JC-1)135. The accumulation of these dyes in
mitochondria are inversely proportional to the MMP, with increased accumulation in
hyperpolarized mitochondria135,136. MitoTracker Red CMXRos (MTR) is a chloromethylX-rosamine derivative that is cell permeant and accumulates in active mitochondria (i.e.
dependent of the MMP)137. However, the selective binding of MTR has been debated. One
comparative study of fluorescent dyes suggested that MTR also covalently binds with
sulfhydryl groups in mitochondria, leadings to potential misinterpretation of the MMP138.
However, other more recent comparative studies139,140 suggest both JC-1 and MTR
readouts pertaining to MMP changes are comparable.
Another variable not addressed in the experiments conducted in this study include the
absence of a positive control for sulfatide toxicity and mitochondrial dysfunction.
Chemical agents (such as hydrogen peroxide) known to induce increased generation of
ROS, causing mitochondrial dysfunction are important as they validate the methodology
and assessment criteria for the image analyses performed in this study. Lastly, all the
mitochondrial work done in this study is based on static image analyses. Given that
mitochondria are dynamic organelles, a more informative approach to understand the
mitochondrial morphological changes would be to track live mitochondria. Additionally,
given the well-established knowledge of the markers of autophagy24, mitophagy141,142 and
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proteins involved in the fusion and fission processes143, a more rigorous study of either
mRNA expression or protein expression would complement the findings in this study.

4.6

Future Studies

This study established a murine in vitro model to specifically study the PNS disease in
MLD. Two main cellular functions were broadly assessed: mitochondrial morphology and
innate immune responses to sulfatide exposure. I characterized the mitochondrial
morphological changes, phagocytic capability, and cytokine secretion in the murine MLD
cell model over the course of 24 hours under increasing sulfatide exposure.
Both TNF-α and IL-1β are pro-inflammatory cytokines, often associated with pathogenic
conditions in different LSDs. Sporadic studies on neuroinflammation in MLD have shown
increased secretion of these cytokines when there is abnormal sulfatide metabolism. We
demonstrated an increase in secretion of both cytokines in MLD cells at the 12- and 24hour time points after sulfatide exposure. Future studies should look to address the
persistence of the cytokine secretion in vivo and in vitro at prolonged time points after
sulfatide exposure. This will enable us to understand whether MLD cells/ tissues are
experiencing a chronic neuroinflammatory state.
No differences were observed in the phagocytosis of fluorescent beads after 3 hours of
exposure to sulfatide. This finding cannot be used as a conclusive statement about the
ability of the MLD cells to phagocytose material. Phagocytosis involves a series of intricate
process that are interdependent. We chose to conduct the assay at a very early time point
after sulfatide exposure, based on findings from other LSDs. A more detailed assessment
of phagocytosis at longer time points after sulfatide exposure would be useful in
understanding the potential secondary mechanisms at play in the PNS, as it relates to innate
myelin repair mechanisms. Extending to human PNS-associated regions and/or cells, a
better understanding of possible causes for the clinical variability seen in patients can be
assessed.
The MLD cells displayed persistent swollen and fragmented mitochondrial morphology
for up to 24 hours after exposure to sulfatide. Whereas unaffected cells showed an increase
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and subsequent decrease to baseline levels of swollen and fragmented mitochondria. As
mitochondrial morphology is tightly linked to function, this suggests that mitochondrial
function is abnormal in the disease-affected cells. Future experiments should look to
characterize the protein and/or mRNA expression levels of fusion and fission associated
proteins such as Opa1, Drp1, Mfn1, and Mfn2, in addition to the changes in Ca2+ and ROS
production of the cells exposed to sulfatide for prolonged periods of time.
Additionally, the presence of contact sites between lysosomes and mitochondria on the
respective plasma membranes is established as is the knowledge that mitochondria are
morphologically dynamic. Membrane integrity is critical for mitochondria undergoing
fusion and fission. Prolonged lysosomal storage has been hypothesized to cause
irregularities in the membrane integrities of other cellular organelles. Balboa et al.144
demonstrated an increase in the lysosome-mitochondria contact sites in Niemann Pick C
that lead to accumulation of lipids in both the lysosomes and mitochondria causing a dual
effect, resulting in apoptosis. Another study in GM1 gangliosidosis (another LSD)
identified increased permeability in mitochondria membranes as a result of ER-induced
increased Ca2+ levels in the cytoplasm145,146. Both these studies and the existence of these
contact sites are fascinating in the context of MLD. Given the suggested mitochondrial
involvement identified in our study, further evaluation of the Ca2+ status and contact sites
in MLD cells is warranted. Deeper understanding of the mitochondrial function changes
can potentially aid the development of combination therapies aimed to address both the
enzyme deficiency and mitochondrial dysfunction.

4.7

Significance and Conclusion

MLD is a rare inherited metabolic disease that manifests as a primarily neurological
condition, with a heterogenous clinical presentation. In particular, the presentation of
peripheral neuropathy is varied and unpredictable. Despite extensive efforts in designing
and optimizing gene therapy vectors, MLD remains fatal. For reasons presently unknown,
numerous clinical trials centered around gene or cell-based gene therapy have been less
efficacious at addressing the PNS disease, despite showing improvements in the CNS.
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Advances in technology and our knowledge of the interdependencies at a cellular level
provide a great platform for us to improve our understanding of the disease. Our study
provides insight into some cellular abnormalities in MLD cells, in addition to the known
enzyme deficiency. We demonstrate a clear difference in the disease-affected cells’ ability
to restore cellular homeostasis after exposure to exogenously introduced sulfatide. Our
findings support the growing body of evidence demonstrating a link between mitochondrial
and lysosomal function in LSDs. The finding of mitochondrial involvement and increased
inflammatory response under sulfatide-induced stress conditions further support the need
to refine our understanding of the PNS disease, independent from CNS involvement.
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Appendices

Supplementary Figure 1. Variant summary in MLD. The blue lines represent variants identified through literature that have
been suggested to be associated with the presence of peripheral neuropathy. Variants include: c.826A>C (p.Thre288Pro,
homozygous); c.1223C3>T(p.Thr408Ile); c.661 T>G (p.Phe221Val, homozygous); c.878G>A (p.Arg293Gln); c.1465 T>G
(p.Cys489Gly).
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Supplementary Figure 2. Schwann cell media treatment of mesenchymal stromal cells. cbMSC-ARSA-WT and cbMSCARSA-KO cells were cultured in Mesencult media (normal mesenchymal cell media), N20 media (made in lab for immortalized
oligodendrocyte cell line) and Schwann cell media (purchased from ScienCell). Scale bar is 50 µm.

115

Supplementary Figure 3. TUNNEL staining of primary neural cells in ARSA-KO mouse. Primary neural cells were isolated from

the cerebellar regions of ARSA-KO mice and treated with sulfatide for a period of 1-3 hrs. Data was generated by Dr. Jiahui
Lui, Cathy Regan and Dr. Bruce Gordon (Bethany’s Hope Leukodystrophy Laboratory).
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Supplementary Figure 4. Phagocytosis net effect with fluorescent E. coli in sulfatide treated cbMSC-ARSA-KO cells. Assay was

performed 3 hours following sulfatide treatment. Fluorescence of FITC-labeled E. coli. was measured on a microplate reader
(Varioskan 3.01.15, ThermoFisher, UK). Data are expressed as mean ± SEM. No significant differences were found.

117

0

1

Animal Use Protocol (AUP)

2

3

Curriculum Vitae

4

